-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HKMbld8XvbOlojbkLjmmY1xGjrHO6lNpTMRmB5jxvQbBO/OcPM7xEmzE/pzWlBNk /G1MbMtubWfaded266ONGg== 0001193125-07-161829.txt : 20070725 0001193125-07-161829.hdr.sgml : 20070725 20070725170254 ACCESSION NUMBER: 0001193125-07-161829 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20070725 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070725 DATE AS OF CHANGE: 20070725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PSS WORLD MEDICAL INC CENTRAL INDEX KEY: 0000920527 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 592280364 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23832 FILM NUMBER: 07999882 BUSINESS ADDRESS: STREET 1: 4345 SOUTHPOINT BLVD STREET 2: STE 250 CITY: JACKSONVILLE STATE: FL ZIP: 32216 BUSINESS PHONE: 9043323000 MAIL ADDRESS: STREET 1: 4345 SOUTHPOINT BLVD STREET 2: STE 250 CITY: JACKSONVILLE STATE: FL ZIP: 32216 FORMER COMPANY: FORMER CONFORMED NAME: PHYSICIAN SALES & SERVICE INC /FL/ DATE OF NAME CHANGE: 19940318 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


FORM 8-K

 


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 25, 2007

 


PSS WORLD MEDICAL, INC.

(Exact name of Registrant as specified in its charter)

 


Commission File Number: 0-23832

 

Florida   59-2280364

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification Number)

 

 

4345 Southpoint Blvd.

Jacksonville, Florida

 

32216

 
(Address of principal executive offices)   (Zip code)

Registrant’s telephone number, including area code (904) 332-3000

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 2.02 Disclosure of Results of Operations and Financial Condition.

On July 25, 2007, PSS World Medical, Inc. (the “Company”) issued a press release in which the Company announced its financial results for the three months ended June 29, 2007. This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. In connection with the press release, the Company has also made available certain supplemental financial information (“the Financial Supplement”) for the three months ended June 29, 2007, which may be found on the Company’s website at www.pssd.com. This Financial Supplement is included as Exhibit 99.2 to this report and is incorporated herein by reference.

In accordance with General Instruction B.6 of Form 8-K, the information included or incorporated in this report, including Exhibit 99.1 and Exhibit 99.2, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

The press release and Financial Supplement contain financial measures that are not in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company has provided reconciliations within the press release and Financial Supplement of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company provides non-GAAP financial measures to supplement its consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures are intended to supplement the user’s overall understanding of the Company’s current financial performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company’s core operating results or business performance. However, these non-GAAP financial measures are not intended to supercede or replace the Company’s GAAP results. A detailed reconciliation of the GAAP results to the non-GAAP results is provided within the financial supplement.


Item 9.01 Financial Statements and Exhibits.

 

 

Exhibit

Number

 

Description

99.1   Press Release dated July 25, 2007 with respect to the Registrant’s financial results for the three months ended June 29, 2007.
99.2   Financial Supplement for the three months ended June 29, 2007.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 25, 2007

 

PSS WORLD MEDICAL, INC.

By:

 

/s/ David M. Bronson

Name:

  David M. Bronson

Title:

 

Executive Vice President and

Chief Financial Officer


EXHIBIT INDEX

 

99.1   Press Release dated July 25, 2007.
99.2   Financial Supplement for the three months ended June 29, 2007
EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO

N E W S    R E L E A S E

 

Contact:   Robert C. Weiner
  Vice President, Investor Relations
  904-332-3287

PSS WORLD MEDICAL REPORTS RESULTS

FOR FISCAL 2008 FIRST QUARTER

Fiscal 2008 First Quarter Highlights:

 

   

Consolidated net sales growth of 6.2%

 

  ¡  

Physician Business net sales growth of 7.7%

 

  ¡  

Elder Care Business net sales increased by 3.1%

 

   

Consolidated operating income of $14.5 million

 

  ¡  

Physician Business operating margin of 6.0%

 

  ¡  

Elder Care Business operating margin of 3.5%

 

   

Consolidated cash flow from operations of $19.4 million

Jacksonville, Florida (July 25, 2007) – PSS World Medical, Inc. (NASDAQ GS:PSSI) announced today its results for the fiscal 2008 first quarter ended June 29, 2007.

Net sales for the three months ended June 29, 2007, were $438.9 million, an increase of 6.2%, compared with net sales of $413.1 million for the three months ended June 30, 2006. Net sales for the three months ended June 29, 2007, for the Physician Business increased by 7.7%, while net sales for the Elder Care Business increased by 3.1%. Income from operations for the three months ended June 29, 2007 was $14.5 million compared with income from operations for the three months ended June 30, 2006, of $18.7 million. Net income for the three months ended June 29, 2007 was $8.7 million, or $0.13 per diluted share, compared with net income for the three months ended June 30, 2006, of $11.0 million, or $0.16 per diluted share.

The Company noted that the first quarter operating income was negatively impacted by the following: costs associated with new state pedigree laws, particularly within the state of Florida, for the sale and distribution of pharmaceutical products ($2.7 million); costs associated with integration of a recently acquired company ($0.7 million); sales training and marketing program costs to launch a new product category in its Physician Business ($1.2 million); lower than expected equipment sales in its Physician Business, primarily resulting from lost selling time used for program launch and training ($0.5 million). The Company’s revised goal for fiscal year 2008 consolidated GAAP diluted earnings per share is a range of $0.81 to $0.85.

David A. Smith, Chairman and Chief Executive Officer, commented, “This first quarter set back has challenged and energized the determination of our officer team to execute our plans for the next three quarters of the year. Our field teams are very pleased and excited by the new programs and products we have invested in for their future growth. We have good momentum in the business, a solid plan, and are attractively positioned for future strategic growth.”

 

-MORE-


PSSI Reports Results For Fiscal 2008 First Quarter

Page 2

July 25, 2007

 

David M. Bronson, Executive Vice President and Chief Financial Officer, commented, “The costs we recognized in this first quarter tended to mask some otherwise very good performance. Other than the shortfall in equipment revenue, traction in our key marketing strategies was very strong with good revenue growth in Select™, pharmaceuticals, and home care. Continued focus on working capital generated operating cash flow that exceeded our expectations. Our operating and shared service teams are focused on building on that momentum to meet our earnings targets for the remainder of the fiscal year.”

The Company has today filed an SEC Form 8-K including a copy of this press release and its related Fiscal 2008 First Quarter Financial Workbook, which contains GAAP and non-GAAP financial measures, and is available on the Company’s website, www.pssworldmedical.com.

A listen-only simulcast as well as a 90-day online replay of PSS World Medical’s fiscal 2008 first quarter conference call can be found in the Investor Relations/Financial Information sections of the Company’s websites, www.pssworldmedical.com or www.pssd.com, respectively, under the heading “Events and Presentations,” or at www.opencompany.info, on July 26, 2007, beginning at 8:30 a.m. Eastern time.

PSS World Medical, Inc. is a national distributor of medical products to physicians and elder care providers through its two business units. Since its inception in 1983, PSS has become a leader in the two market segments that it serves with a focused market approach to customer services, a consultative sales force, strategic acquisitions, strong arrangements with product manufacturers and a unique culture of performance.

Additional financial information pertaining to PSS World Medical financial results may be found by visiting the Investor Relations/Financial Information sections of the Company’s websites, www.pssworldmedical.com or www.pssd.com, respectively, under the heading “Events and Presentations.” If you should need assistance accessing the information, please call Investor Relations at 904-332-3000.

All statements in this release that are not historical facts, including, but not limited to, statements regarding anticipated growth in revenue, gross and operating margins, and earnings, statements regarding the Company’s current business strategy, the Company’s ability to complete and integrate acquired businesses and generate acceptable rates of return, the Company’s projected sources and uses of cash, and the Company’s plans for future development and operations, are based upon current expectations. Specifically, forward-looking statements in this Press Release include, without limitation, the Company’s expected results in GAAP EPS, revenue, operating incomes and operating margins for continuing operations for both the consolidated company and for each of its businesses in fiscal year 2008; the expected operational cash flow in fiscal year 2008; the ability to sustain revenue growth and expected growth rates of the marketing programs in its Physician and Elder Care Businesses; the Company’s decision to not participate in the sale of flu vaccine in fiscal year 2008; expected pharmaceutical product sales in Florida and all other of the 50 U.S. states in fiscal year 2008; expected sales growth from revenues derived from home care, hospice and assisted living customers; expected efficiency, customer acceptance and profitability derived from the Company’s global product sourcing strategy; expected revenue, income and profitability derived from the Company’s strategy to invest and participate in the marketing and sales of healthcare information technology products and services (HCIT); the expectation for acquired assets to meet performance, integration, revenue and profitability assumptions and targets; as well as other expectations of growth and financial and operational performance. These statements are forward-looking in nature and involve a number of risks and uncertainties. Actual results may differ materially. Among the factors that could cause results to differ materially are the following: pricing and customer credit quality pressures; the loss of any of our distributorship agreements and our reliance on relationships with our suppliers and vendors; our reliance on a limited number of chain business elder care customers; the availability of sufficient capital to finance the Company’s business plans on terms satisfactory to the Company; lower revenue and earnings that may result from competition; the ability of the Company to adequately defend or reach a settlement on outstanding litigation matters and investigations involving the Company or its management; changes in labor, equipment and capital costs; changes in legislation and regulations affecting the Company’s business, such as the Medicare cliffs, changes in malpractice insurance rates and tort reform; future acquisitions or strategic partnerships; general business, competitive and economic factors and conditions; and other factors described from time to time in the Company’s reports filed with the Securities and Exchange Commission. Many of these factors are outside the control of the Company. The Company wishes to caution readers not to place undue reliance on any such forward looking statements, which statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. The Company also wishes to caution readers that it undertakes no duty or is under no obligation to update or revise any forward-looking statements.

 

-MORE-


PSSI Reports Results For Fiscal 2008 First Quarter

Page 3

July 25, 2007

 

PSS WORLD MEDICAL, INC.

Unaudited Condensed Consolidated Statements of Operations

(In millions, except per share and share data)

 

     Three Months Ended  
  

June 29,

2007

   

June 30,

2006

 

Net sales

   $ 438.9     $ 413.1  

Cost of goods sold

     311.2       293.2  
                

Gross profit

     127.7       119.9  

General and administrative expenses

     83.6       73.7  

Selling expenses

     29.6       27.5  
                

Income from operations

     14.5       18.7  
                

Other (expense) income:

    

Interest expense

     (1.4 )     (1.4 )

Interest and investment income

     0.5       0.1  

Other income

     0.6       0.5  
                

Other expense

     (0.3 )     (0.8 )
                

Income before provision for income taxes

     14.2       17.9  

Provision for income taxes

     5.5       6.9  
                

Net income

   $ 8.7     $ 11.0  
                

Earnings per share – basic

   $ 0.13     $ 0.16  
                

Earnings per share – diluted

   $ 0.13     $ 0.16  
                

Weighted average shares (in thousands):

    

Basic

     66,793       67,310  

Diluted

     68,765       68,947  

 

-MORE-


PSSI Reports Results For Fiscal 2008 First Quarter

Page 4

July 25, 2007

 

PSS WORLD MEDICAL, INC.

Condensed Consolidated Balance Sheets

(In millions, except per share and share data)

 

     June 29,
2007
   March 30,
2007
     (Unaudited)     
ASSETS      

Current Assets:

     

Cash and cash equivalents

   $ 24.0    $ 46.7

Accounts receivable, net

     222.7      222.8

Inventories

     187.5      174.1

Deferred tax assets, net

     9.0      8.8

Prepaid expenses and other

     34.2      34.4
             

Total current assets

     477.4      486.8

Property and equipment, net

     89.3      88.6

Other Assets:

     

Goodwill and intangibles, net

     141.3      137.1

Other

     98.4      62.5
             

Total assets

   $ 806.4    $ 775.0
             

LIABILITIES AND SHAREHOLDERS’ EQUITY

     

Current Liabilities:

     

Accounts payable

   $ 144.6    $ 131.3

Accrued expenses

     33.1      37.2

Current portion of long-term debt

     2.1      2.2

Other current liabilities

     15.3      11.5
             

Total current liabilities

     195.1      182.2

Long-term debt, excluding current portion

     150.5      150.7

Other noncurrent liabilities

     70.4      61.2
             

Total liabilities

     416.0      394.1
             

Shareholders’ Equity:

     

Preferred stock, $0.01 par value; 1,000,000 shares authorized, no shares issued and outstanding

     —        —  

Common stock, $0.01 par value; 150,000,000 shares authorized, 67,329,723 and 67,179,475 shares issued and outstanding at June 29, 2007, and March 30, 2007, respectively

     0.7      0.7

Additional paid-in capital

     301.1      300.0

Retained earnings

     88.6      80.2
             

Total shareholders’ equity

     390.4      380.9
             

Total liabilities and shareholders’ equity

   $ 806.4    $ 775.0
             

 

-MORE-


PSSI Reports Results For Fiscal 2008 First Quarter

Page 5

July 25, 2007

 

PSS WORLD MEDICAL, INC.

Unaudited Condensed Consolidated Statements of Cash Flows

(In millions)

 

     Three Months Ended  
     June 29,
2007
    June 30,
2006
 

Cash Flows From Operating Activities:

    

Net income

   $ 8.7     $ 11.0  

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation

     4.6       4.1  

Provision for deferred income taxes

     0.2       4.4  

Amortization of intangible assets

     1.5       1.5  

Provision for doubtful accounts

     1.0       0.1  

Noncash compensation expense

     0.7       0.3  

Amortization of debt issuance costs

     0.3       0.4  

Provision for deferred compensation

     1.3       0.4  

Changes in operating assets and liabilities, net of effects from business combination:

    

Accounts receivable, net

     2.0       2.6  

Inventories

     (11.3 )     2.8  

Prepaid expenses and other current assets

     0.8       (4.6 )

Other assets

     (7.0 )     (0.2 )

Accounts payable

     8.5       (16.8 )

Accrued expenses and other liabilities

     8.0       (2.0 )
                

Net cash provided by operating activities

     19.3       4.0  
                

Cash Flows From Investing Activities:

    

Payments for business combinations, net of cash acquired

     (14.8 )     (0.1 )

Payments for investment in preferred stock

     (22.5 )     —    

Capital expenditures

     (4.9 )     (4.6 )

Payments for non-solicitation agreements

     —         (0.5 )

Payments for signing bonuses

     (0.1 )     —    
                

Net cash used in investing activities

     (42.3 )     (5.2 )
                

Cash Flows From Financing Activities:

    

Proceeds from exercise of options

     0.4       2.5  

Excess tax benefits from share-based compensation agreements

     0.1       1.2  

Payments under capital lease obligations

     (0.2 )     (0.1 )

Other

     —         1.5  
                

Net cash provided by financing activities

     0.3       5.1  
                

Net increase in cash and cash equivalents

     (22.7 )     3.9  

Cash and cash equivalents, beginning of period

     46.7       23.9  
                

Cash and cash equivalents, end of period

   $ 24.0     $ 27.8  
                

 

-END-

EX-99.2 3 dex992.htm FINANCIAL SUPPLEMENT FOR THE THREE MONTHS ENDED JUNE 29, 2007 Financial Supplement for the three months ended June 29, 2007

Exhibit 99.2

LOGO

Financial Data Workbook

For the First Quarter of Fiscal Year 2008 ending June 29, 2007


PSS World Medical, Inc.

As of June 29, 2007

Current Fiscal Year

(in thousands, except per share data)

 

      Fiscal 2007  
     Q1  

Net Sales

   $ 438,910  

Cost of Goods Sold

     311,227  
        

Gross Profit

     127,683  

General & Administrative Expenses

     83,600  

Selling Expenses

     29,551  
        

Income from operations

     14,532  

Interest Expense

     (1,358 )

Interest & Investment Income

     528  

Other Income

     544  
        

Income from Operations before Income Taxes

     14,246  

Provision for Income Taxes

     5,559  
        

Net Income

   $ 8,687  
        

Earnings per share - Basic:

  
        

Net Income

   $ 0.13  
        

Earnings per share - Diluted:

  
        

Net Income

   $ 0.13  
        

WASO - Basic

     66,793  

WASO - Diluted

     68,765  

Net Sales by Segment:

  

Physician Business

   $ 306,245  

Elder Care Business

     132,665  
        
   $ 438,910  
        

Billing Days:

     64  

Net Sales Per Billing Day:

  

Physician Business

   $ 4,785  

Elder Care Business

     2,073  
        
   $ 6,858  
        

Numbers may not foot due to rounding differences.


PSS World Medical, Inc.

As of June 29, 2007

(in thousands, except per share data)

 

    Fiscal 2005     Fiscal 2006           Fiscal 2007  
    Q1     Q2     Q3     Q4     Total     Q1     Q2     Q3     Q4     Total     Q1     Q2     Q3     Q4     Total  

Net Sales (1)

  $ 330,361     $ 364,267     $ 377,842     $ 401,299     $ 1,473,769     $ 387,129     $ 385,819     $ 423,781     $ 422,688     $ 1,619,417     $ 413,135     $ 427,059     $ 458,421     $ 443,024     $ 1,741,639  

Cost of Goods Sold

    234,585       258,945       268,675       288,209       1,050,414       276,654       273,512       303,707       298,219       1,152,092       293,233       303,203       335,186       310,007       1,241,629  
                                                                                                                       

Gross Profit

    95,776       105,322       109,167       113,090       423,355       110,475       112,307       120,074       124,469       467,325       119,902       123,856       123,235       133,017       500,010  

General & Administrative Expenses (2)

    60,948       64,300       68,827       68,130       262,205       70,337       69,279       72,053       75,639       287,308       73,664       73,391       75,222       78,423       300,700  

Selling Expenses

    23,453       24,625       25,082       26,431       99,591       25,774       26,217       27,469       28,148       107,608       27,498       28,878       30,140       30,307       116,823  
                                                                                                                       

Income from operations

    11,375       16,397       15,258       18,529       61,559       14,364       16,811       20,552       20,682       72,409       18,740       21,587       17,873       24,287       82,487  

Interest Expense

    (1,942 )     (1,817 )     (1,737 )     (1,360 )     (6,856 )     (1,509 )     (1,358 )     (1,561 )     (1,456 )     (5,884 )     (1,406 )     (1,336 )     (1,320 )     (1,284 )     (5,346 )

Interest & Investment Income

    111       89       12       5       217       99       111       75       138       423       101       282       426       385       1,194  

Other Income

    343       252       378       261       1,234       457       1,750       435       504       3,146       469       429       517       591       2,006  
                                                                                                                       

Income from Continuing Operations before Income Taxes

    9,887       14,921       13,911       17,435       56,154       13,411       17,314       19,501       19,868       70,094       17,904       20,962       17,496       23,979       80,341  

Provision for Income Taxes

    3,962       6,149       (525 )     7,184       16,770       5,271       6,529       7,080       6,957       25,837       6,949       8,187       6,376       8,348       29,860  
                                                                                                                       

Income from Continuing Operations

    5,925       8,772       14,436       10,251       39,384       8,140       10,785       12,421       12,911       44,257       10,955       12,775       11,120       15,631       50,481  

Total loss from discontinued operations

    (1,708 )     —         1,295       —         (412 )     —         —         —         —         —         —         —         —         —         —    
                                                                                                                       

Net Income

  $ 4,217     $ 8,772     $ 15,731     $ 10,251     $ 38,972     $ 8,140     $ 10,785     $ 12,421     $ 12,911     $ 44,257     $ 10,955     $ 12,775     $ 11,120     $ 15,631     $ 50,481  
                                                                                                                       

Earnings (loss) per share—Basic:

                             

Income from Continuing Operations

  $ 0.09     $ 0.14     $ 0.22     $ 0.16     $ 0.61     $ 0.13     $ 0.16     $ 0.19     $ 0.19     $ 0.67     $ 0.16     $ 0.19     $ 0.17     $ 0.23     $ 0.75  

Total loss from discontinued operations

    (0.03 )     —         0.02       —         (0.01 )     —         —         —         —         —         —         —         —         —         —    
                                                                                                                       

Net Income

  $ 0.06     $ 0.14     $ 0.24     $ 0.16     $ 0.60     $ 0.13     $ 0.16     $ 0.19     $ 0.19     $ 0.67     $ 0.16     $ 0.19     $ 0.17     $ 0.23     $ 0.75  
                                                                                                                       

Earnings (loss) per share—Diluted:

                             

Income from Continuing Operations

  $ 0.09     $ 0.13     $ 0.22     $ 0.16     $ 0.60     $ 0.12     $ 0.16     $ 0.19     $ 0.19     $ 0.66     $ 0.16     $ 0.18     $ 0.16     $ 0.23     $ 0.73  

Total loss from discontinued operations

    (0.03 )     —         0.02       —         (0.01 )     —         —         —         —         —         —         —         —         —         —    
                                                                                                                       

Net Income

  $ 0.06     $ 0.13     $ 0.24     $ 0.16     $ 0.59     $ 0.12     $ 0.16     $ 0.19     $ 0.19     $ 0.66     $ 0.16     $ 0.18     $ 0.16     $ 0.23     $ 0.73  
                                                                                                                       

WASO—Basic

    64,890       64,358       64,305       64,656       64,547       64,877       65,392       65,779       66,546       65,643       67,310       67,453       67,054       67,059       67,219  

WASO—Diluted

    66,056       65,267       65,366       65,786       65,607       65,860       66,487       66,931       68,062       66,887       68,947       69,478       69,458       69,419       69,325  

Net Sales by Segment:

                             

Physician Business

  $ 216,705     $ 237,370     $ 243,439     $ 261,502     $ 959,016     $ 250,544     $ 255,422     $ 290,010     $ 290,844     $ 1,086,820     $ 284,438     $ 300,813     $ 329,160     $ 313,109     $ 1,227,520  

Elder Care Business

    113,656       126,897       134,403       139,797       514,753       136,585       130,397       133,771       131,844       532,597       128,697       126,246       129,261       129,915       514,119  
                                                                                                                       
  $ 330,361     $ 364,267     $ 377,842     $ 401,299     $ 1,473,769     $ 387,129     $ 385,819     $ 423,781     $ 422,688     $ 1,619,417     $ 413,135     $ 427,059     $ 458,421     $ 443,024     $ 1,741,639  
                                                                                                                       

Billing Days:

    62       65       61       65       253       64       63       62       64       253       64       63       62       64       253  

Net Sales Per Billing Day:

                             

Physician Business

  $ 3,495     $ 3,652     $ 3,991     $ 4,023     $ 3,791     $ 3,915     $ 4,054     $ 4,678     $ 4,544     $ 4,296     $ 4,444     $ 4,775     $ 5,309     $ 4,892     $ 4,852  

Elder Care Business

    1,833       1,952       2,203       2,151       2,035       2,134       2,070       2,158       2,060       2,105       2,011       2,004       2,085       2,030       2,032  
                                                                                                                       
  $ 5,328     $ 5,604     $ 6,194     $ 6,174     $ 5,826     $ 6,049     $ 6,124     $ 6,836     $ 6,604     $ 6,401     $ 6,455     $ 6,779     $ 7,394     $ 6,922     $ 6,884  
                                                                                                                       

(1) Quarterly net sales for fiscal year 2007 were adjusted in the fourth quarter of 2007 from previously reported amounts. During the fourth quarter of fiscal year 2007, the Company properly reclassified certain transactions from cost of sales to net sales. Such adjustments were deemed immaterial on quarterly net sales.

 

3


PSS World Medical, Inc.

As of June 29, 2007

SelectTM Net Sales

(in thousands)

 

     Fiscal
2003
   Fiscal
2004
   Fiscal
2005
   Fiscal
2006
   Fiscal
2007

Consolidated Select Sales

   $ 101,883    $ 121,211    $ 137,540    $ 157,296    $ 185,844


PSS World Medical, Inc.

As of June 29, 2007

Cost to Serve Expenses

(in thousands)

 

     Fiscal
2003
    Fiscal
2004
    Fiscal
2005
    Fiscal
2006
    Fiscal
2007
 

Consolidated Cost to Serve

   $ 227,723     $ 240,084     $ 261,179     $ 285,054     $ 294,001  

As a Percentage of Net Sales

     19.3 %     17.8 %     17.7 %     17.6 %     16.9 %

Cost to Serve includes warehouse, general and administrative, customer freight charges and other expenses related to cost to serve.


PSS WORLD MEDICAL, INC.

SEGMENT INFORMATION

June 29, 2007

(in thousands)

 

     Three Months Ended  
     6/29/2007     6/30/2006  

NET SALES:

    

Physician Business

   306,245     284,438  

Elder Care Business

   132,665     128,696  
            

Total Net Sales

   438,910     413,135  
            
BILLING DAYS:    64     64  
NET SALES PER BILLING DAY:     

Physician Business

   4,785     4,444  

Elder Care Business

   2,073     2,011  
            

Total Net Sales Per Billing Day

   6,858     6,455  
            
INCOME FROM OPERATIONS:     

Physician Business

   18,516     18,608  

Elder Care Business

   4,586     4,883  

Corporate Shared Services

   (8,570 )   (4,751 )
            

Total Income from operations

   14,532     18,740  
            
DEPRECIATION:     

Physician Business

   2,077     1,926  

Elder Care Business

   1,145     1,031  

Corporate Shared Services

   1,377     1,137  
            

Total Depreciation

   4,599     4,094  
            
AMORTIZATION OF INTANGIBLE AND OTHER ASSETS:     

Physician Business

   782     772  

Elder Care Business

   647     698  

Corporate Shared Services

   29     35  
            

Total amortization of intangible and other assets

   1,458     1,505  
            
PROVISION FOR DOUBTFUL ACCOUNTS:     

Physician Business

   604     (64 )

Elder Care Business

   346     156  

Corporate Shared Services

   —       —    
            

Total provision for doubtful accounts

   950     92  
            
INTEREST EXPENSE:     

Physician Business

   1,072     1,017  

Elder Care Business

   1,959     1,959  

Corporate Shared Services

   (1,673 )   (1,570 )
            

Total interest expense

   1,358     1,406  
            
INTEREST AND INVESTMENT INCOME:     

Physician Business

   —       —    

Elder Care Business

   3     6  

Corporate Shared Services

   525     95  
            

Total interest and investment income

   528     101  
            
PROVISION (BENEFIT) FOR INCOME TAXES:     

Physician Business

   6,967     6,956  

Elder Care Business

   1,029     1,154  

Corporate Shared Services

   (2,437 )   (1,161 )
            

Total provision for income taxes

   5,559     6,949  
            

Numbers may not foot due to rounding differences.


PSS World Medical, Inc.

Current Fiscal Year Balance Sheet

(in thousands)

Consolidated

 

      As of
6/29/07
ASSETS   

Cash

   23,954

Accounts Receivable, net

   222,699

Inventory, net

   187,499

Deferred Tax Assets

   8,987

Other Current Assets

   34,257
    

Total Current Assets

   477,396
    

Property and Equipment, net

   89,347

Intangibles, net

   30,280

Goodwill

   110,993

Other Long-Term Assets

   98,380
    

Total Long-Term Assets

   329,000
    

Total Assets

   806,396
    
LIABILITIES & EQUITY   

Accounts Payable

   144,572

Accrued Expenses

   33,099

Current Maturities of Long-Term Debt

   2,132

Other Current Liabilities

   15,267
    

Total Current Liabilities

   195,070
    

Long-Term Debt

   150,527

Deferred Tax Liability Non-Current

   —  

Other Long-Term Liabilities

   70,414
    

Total Long-Term Liabilities

   220,941
    

Total Liabilities

   416,011
    

Total Equity

   390,385
    

Total Liabilities & Equity

   806,396
    

Numbers may not foot due to rounding differences.


PSS World Medical, Inc.

Balance Sheet Trend

(in thousands)

Consolidated

 

    Fiscal 2005   Fiscal 2006   Fiscal 2007

ASSETS

  Jun-04   Sep-04   Dec-04   Mar-05   Jun-05   Sep-05   Dec-05   Mar-06   Jun-06   Sep-06   Dec-06   Mar-07

Cash

  63,112   45,591   13,657   17,888   23,836   17,466   26,651   23,867   27,784   45,678   54,904   46,658

Accounts Receivable, net

  182,639   197,423   209,342   217,350   208,642   213,585   207,659   208,964   206,405   225,536   219,822   222,776

Inventory, net

  112,653   113,384   147,470   134,110   132,684   136,450   167,407   173,458   170,612   172,127   186,193   174,130

Deferred Tax Assets

  38,594   33,301   32,206   29,014   29,113   20,183   14,298   12,959   11,181   9,042   7,379   8,776

Other Current Assets

  13,596   10,016   18,567   19,451   22,182   25,822   27,937   33,827   32,876   39,288   37,329   34,434
                                               

Total Current Assets

  410,594   399,715   421,242   417,813   416,457   413,506   443,952   453,075   448,858   491,671   505,627   486,774
                                               

Property and Equipment, net

  70,792   73,362   76,453   81,105   84,173   86,840   86,475   87,663   88,214   87,291   85,885   88,627

Intangibles, net

  10,737   12,824   22,419   21,858   21,217   34,427   35,395   34,345   33,350   32,343   31,186   29,758

Goodwill

  71,631   71,646   79,542   85,617   86,273   103,420   105,452   105,521   106,519   106,819   106,971   107,366

Other Long-Term Assets

  39,555   40,794   41,691   39,965   47,315   50,862   53,665   56,371   —     —     —     2
                                               

Total Long-Term Assets

  192,715   198,626   220,105   228,545   238,978   275,549   280,987   283,900   283,066   281,388   282,105   288,201
                                               

Total Assets

  603,309   598,341   641,347   646,358   655,435   689,055   724,939   736,975   731,924   773,059   787,732   774,975
                                               
    Fiscal 2005   Fiscal 2006   Fiscal 2007

LIABILITIES & EQUITY

  Jun-04   Sep-04   Dec-04   Mar-05   Jun-05   Sep-05   Dec-05   Mar-06   Jun-06   Sep-06   Dec-06   Mar-07

Accounts Payable

  105,057   105,608   127,465   109,649   115,455   118,953   141,622   139,227   122,449   145,767   162,338   131,330

Accrued Expenses

  29,667   33,610   36,085   44,880   26,660   33,196   30,413   34,499   27,748   34,827   31,670   37,224

Current Maturities of Long-Term Debt

  35,052   25,000   25,000   25,000   25,679   27,786   25,788   509   517   1,655   152,154   2,238

Liabilities of Discontinued Operations

  4,809   405   —     —     —     —     —     —     —     —     —     —  

Other Current Liabilities

  12,982   13,360   9,296   9,701   12,661   11,883   11,837   13,639   12,490   13,917   10,730   11,440
                                               

Total Current Liabilities

  187,567   177,983   197,846   189,230   180,455   191,818   209,660   187,874   163,204   196,166   356,892   182,232
                                               

Long-Term Debt

  150,000   150,000   150,000   150,000   151,192   151,113   150,981   150,855   150,725   150,616   460   150,675

Other Long-Term Liabilities

  23,629   25,225   29,359   30,310   35,870   41,179   43,509   49,433   54,274   57,781   62,302   61,207
                                               

Total Long-Term Liabilities

  173,629   175,225   179,359   180,310   187,062   192,292   194,490   200,288   204,999   208,397   62,762   211,882

Total Liabilities

  361,196   353,208   377,205   369,540   367,517   384,110   404,150   388,162   368,203   404,563   419,654   394,114
                                               

Total Equity

  242,113   245,133   264,142   276,818   287,918   304,945   320,789   348,813   363,721   368,496   368,078   380,861
                                               

Total Liabilities & Equity

  603,309   598,341   641,347   646,358   655,435   689,055   724,939   736,975   731,924   773,059   787,732   774,975
                                               

Numbers may not foot due to rounding differences.


PSS World Medical, Inc.

Unaudited Operating Highlights

Current Fiscal Year

(in millions)

 

     Three Months Ended  
     June 29, 2007     June 30, 2006  

Net Sales:

    

Physician Business

   $ 306.2     $ 284.6  

Elder Care Business

     132.7       128.7  
                

Total Net Sales

   $ 438.9     $ 413.3  
                

Income from Operations:

    

Physician Business

   $ 18.5     $ 18.6  

Elder Care Business

     4.6       4.9  

Corporate Shared Services

     (8.6 )     (4.8 )
                

Total income from operations

   $ 14.5     $ 18.7  
                

EBITDA (a)

   $ 22.2     $ 24.8  

Income from operations, as a percentage of net sales

     3.3 %     4.5 %

Consolidated Return on Committed Capital ("ROCC") (b)

     18.2 %     24.4 %

Billing Days

     64       64  

Net Sales Per Billing Day (in thousands):

    

Physician Business

   $ 4,785     $ 4,444  

Elder Care Business

     2,073       2,011  
                

Total Net Sales Per Billing Day

   $ 6,858     $ 6,455  
                

Net Sales Per Billing Day Growth Rate:

    

Physician Business

     7.6 %  

Elder Care Business

     3.1 %  

Total Net Sales Per Billing Day Growth Rate

     6.2 %  
     Annualized  
     June 29, 2007     June 30, 2006  

DSO (c)

    

Physician Business

     41.8       40.2  

Elder Care Business

     51.7       57.5  

DOH (d)

    

Physician Business

     48.4       48.1  

Elder Care Business

     56.9       47.0  

DIP (e)

    

Physician Business

     43.8       42.7  

Elder Care Business

     27.8       28.4  

Cash Conversion Days (f)

    

Physician Business

     46.4       45.6  

Elder Care Business

     80.8       76.1  
     As of  
     June 29, 2007     June 30, 2006  

Operational working capital (g)

   $ 265.6     $ 254.6  

Net Debt:

    

Bank debt

   $ 1.4     $ —    

Other debt

     1.3       1.2  

Convertible senior notes

     150.0       150.0  

Less: Cash and cash equivalents

     (24.0 )     (27.8 )
                

Net Debt

   $ 128.7     $ 123.5  
                

Numbers may not foot due to rounding differences.


PSS World Medical, Inc.

EBITDA Calculation

Current Fiscal Year

(in thousands)

 

     Fiscal 2008
     Q1

Net Income

   $ 8,687

Plus: Interest expense

     1,358

Less: Interest and investment income

     528

Plus: Provision for income taxes

     5,559

Plus: Depreciation

     4,599

Plus: Amortization of intangible assets

     1,458
      

EBITDA

   $ 22,189
      

Numbers may not foot due to rounding differences.


PSS World Medical, Inc.

EBITDA Calculation

(in thousands)

 

    Fiscal 2005     Fiscal 2006     Fiscal 2007  
    Q1     Q2     Q3     Q4     Total FY 2005     Q1     Q2     Q3     Q4     Total FY 2006     Q1     Q2     Q3     Q4     Total FY 2007  

Income from Continuing Operations

  $ 5,925     $ 8,772     $ 14,436     $ 10,251     $ 39,384     $ 8,140     $ 10,785     $ 12,421     $ 12,911     $ 44,257     $ 10,955     $ 12,775     $ 11,120     $ 15,631     $ 50,481  

Plus: Interest expense

    1,942       1,817       1,737       1,360       6,856       1,509       1,358       1,561       1,456       5,884       1,406       1,336       1,320       1,284       5,346  

Less: Interest and investment income

    (111 )     (89 )     (12 )     (5 )     (217 )     (99 )     (111 )     (75 )     (138 )     (423 )     (101 )     (282 )     (426 )     (385 )     (1,194 )

Plus: Provision for income taxes

    3,962       6,149       (525 )     7,184       16,770       5,271       6,529       7,080       6,957       25,837       6,949       8,187       6,376       8,348       29,860  

Plus: Depreciation

    3,482       3,427       3,727       3,605       14,241       3,316       3,468       3,673       3,475       13,932       4,094       4,145       4,215       4,296       16,750  

Plus: Amortization of intangible assets

    836       935       1,278       1,488       4,537       1,361       1,389       1,677       1,871       6,298       1,505       1,472       1,468       1,463       5,908  
                                                                                                                       

EBITDA

  $ 16,036     $ 21,011     $ 20,641     $ 23,883     $ 81,571     $ 19,498     $ 23,418     $ 26,337     $ 26,532     $ 95,785     $ 24,808     $ 27,633     $ 24,073     $ 30,637     $ 107,151  
                                                                                                                       

Numbers may not foot due to rounding differences.


PSS World Medical, Inc.

Return on Committed Capital (ROCC)

Current Fiscal Year

(in thousands)

 

Consolidated

   Fiscal 2008  
     Q1  

Quarterly Average Committed Capital (1)

   363,905  

Return on Committed Capital—Quarterly (2)

   18.2 %

Return:

  

Net Income

   8,687  

Add:

  

Provision for Income Taxes

   5,559  

Interest Expense

   1,358  

Amortization

   1,458  

Interest and Investment Income

   (528 )
      
   16,534  
      

Committed Capital:

  

Total Assets

   806,396  

Less assets excluded:

  

Cash

   (23,954 )

Goodwill and Intangibles, net

   (141,273 )

Total Liabilities

   (416,011 )

Plus liabilities excluded:

  

Current debt

   2,132  

Long-term debt

   150,527  
      
   377,817  
      

(1) Quarterly Average Committed Capital equals the sum of the committed capital of the most recent two quarters, divided by two.
(2) Return on Committed Capital equals Return divided by Committed Capital. Quarterly calculations are annualized.

Numbers may not foot due to rounding differences.


PSS World Medical, Inc.

Return on Committed Capital (ROCC)

(in thousands)

 

Consolidated

  Fiscal 2005     Fiscal 2006     Fiscal 2007  
    Q1     Q2     Q3     Q4     Total FY
2005
    Q1     Q2     Q3     Q4     Total FY
2006
    Q1     Q2     Q3     Q4     Total FY
2007
 

Quarterly Average Committed Capital (1)

  247,761     260,802     280,166     303,738       316,837     322,662     325,748     330,989       340,070     341,619     331,779     338,812    

Annual Average Committed Capital (2)

          274,084             321,764             341,411  

Return on Committed Capital—Quarterly (3)

  20.3 %   27.0 %   24.1 %   26.7 %     20.4 %   24.7 %   27.8 %   27.9 %     24.4 %   27.5 %   23.9 %   31.1 %  

Return on Committed Capital—Annual

          24.6 %           25.4 %           26.5 %

Return:

                             

Income from Continuing Operations before Extraordinary Loss

  5,925     8,772     14,436     10,251     39,384     8,140     10,785     12,421     12,911     44,257     10,955     12,775     11,120     15,631     50,481  

Add:

                             

Provision for Income Taxes

  3,962     6,149     (525 )   7,184     16,770     5,271     6,529     7,080     6,957     25,837     6,949     8,187     6,376     8,348     29,860  

Interest Expense

  1,942     1,817     1,737     1,360     6,856     1,509     1,358     1,550     1,467     5,884     1,406     1,336     1,320     1,284     5,346  

Amortization

  836     934     1,278     1,488     4,536     1,361     1,389     1,677     1,871     6,298     1,500     1,477     1,469     1,462     5,908  

Interest and Investment Income

  (111 )   (89 )   (12 )   (5 )   (217 )   (99 )   (111 )   (64 )   (149 )   (423 )   (101 )   (282 )   (426 )   (385 )   (1,194 )
                                                                                         
  12,554     17,583     16,914     20,278     67,329     16,182     19,950     22,664     23,057     81,853     20,709     23,493     19,859     26,340     90,401  
                                                                                         

Committed Capital:

                             

Total Assets

  603,309     598,341     641,347     646,358     646,358     655,435     689,055     724,939     736,975     736,975     731,924     773,059     787,732     774,975     774,975  

Less assets excluded:

                             

Cash

  (63,112 )   (45,591 )   (13,657 )   (17,888 )   (17,888 )   (23,836 )   (17,466 )   (26,651 )   (23,867 )   (23,867 )   (27,784 )   (45,678 )   (54,904 )   (46,658 )   (46,658 )

Goodwill and Intangibles, net

  (82,368 )   (84,470 )   (101,961 )   (107,475 )   (107,475 )   (107,490 )   (137,847 )   (140,847 )   (139,866 )   (139,866 )   (139,869 )   (139,162 )   (138,157 )   (137,124 )   (137,124 )

Assets of Discontinued Operations

  —       —       —       —       —       —       —       —       —       —       —       —       —       —       —    

DTA from sale of Imaging Business

  (28,444 )   (26,923 )   (26,746 )   (15,758 )   (15,758 )   (10,487 )   (6,184 )   (912 )   (3,614 )   (3,614 )   —             —    

Total Liabilities

  (361,196 )   (353,208 )   (377,205 )   (369,540 )   (369,540 )   (367,517 )   (384,110 )   (404,150 )   (388,162 )   (388,162 )   (368,203 )   (404,563 )   (419,654 )   (394,114 )   (394,114 )

Plus liabilities excluded:

                             

Current debt

  35,052     25,000     25,000     25,000     25,000     25,679     27,786     25,788     509     509     517     1,655     152,154     2,238     2,238  

Long-term debt

  150,000     150,000     150,000     150,000     150,000     151,192     151,113     150,981     150,855     150,855     150,725     150,616     460     150,675     150,675  

Liabilities of Discontinued Operations

  4,809     405     —       —       —       —       —       —       —       —       —       —       —       —       —    
                                                                                         
  258,050     263,554     296,778     310,697     310,697     322,976     322,347     329,148     332,830     332,830     347,310     335,927     327,631     349,992     349,992  
                                                                                         

(1) Quarterly Average Committed Capital equals the sum of the committed capital of the most recent two quarters, divided by two.
(2) Annual Average Committed Capital equals the sum of the committed capital of the most recent two year ends, divided by two.
(3) Return on Committed Capital equals Return divided by Committed Capital. Quarterly calculations are annualized.

Numbers may not foot due to rounding differences.


PSS WORLD MEDICAL, INC.

Footnotes

(a) EBITDA represents net income plus provision for income taxes, interest expense, depreciation, and amortization of intangible assets, less interest and investment income. Management reviews EBITDA when evaluating and comparing the performance of each operating segment on a quarterly basis. Management believes EBITDA is an important measure of liquidity.

(b) ROCC equals return divided by average committed capital. Return is annualized for quarterly calculations. Management reviews ROCC when evaluating and comparing the performance of each operating segment on a quarterly basis. Management believes ROCC is an important measure of profitability and return.

(c) DSO is average accounts receivable divided by average daily net sales. Average accounts receivable is the sum of accounts receivable, net of the allowance for doubtful accounts, at the beginning and end of the most recent four quarters divided by five. Average daily net sales are net sales for the most recent four quarters divided by 360. Southern Anesthesia & Surgical, Inc. (“SAS”) accounts receivable balance of $1.4 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(d) DOH is average inventory divided by average daily cost of goods sold (“COGS”). Average inventory is the sum of inventory at the beginning and end of the most recent four quarters divided by five. Average daily COGS is quarterly COGS for the most recent four quarters divided by 360. SAS inventory balance of $3.9 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(e) DIP is average accounts payable divided by average daily COGS. Average accounts payable is the sum of accounts payable at the beginning and end of the most recent four quarters divided by five. SAS accounts payable balance of $3.8 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(f) Cash Conversion Days is the sum of DSO and DOH less DIP.

(g) Operational working capital equals accounts receivable plus inventory minus accounts payable.

GRAPHIC 4 g40511image1.jpg GRAPHIC begin 644 g40511image1.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`7`"W`P$1``(1`0,1`?_$`+H``0`!!`,!`0$````` M```````)!0<("@(&"P$#!`$!```'`0$```````````````(#!`4&!P@!"1`` M``8!`P,"!`,%!P4!`````0(#!`4&!P`1""$2"3$305$B%($R%7&A(Q8*89&Q M0F)#%]$DU)<96!$``0,#`@0"!@8'`PH'`````0(#!``1!2$&,4$2!U$387&! MD2(4\*&Q,D(CP=%2,Q46".$D-/%B#DZ-4-54V_]H`#`,!``(1 M`Q$`/P#?PTI32E-*4TI32E-*5C'F[E[@/C[-UFF7ZZ)N,G7A0S>AX9I<=(WK M,EZ<#U*6KXUJK23LSQF3?^*^510CFY=SK.$R`)@N$3"9.>PN2TDF(-%.K%F4 M^M1L/9>]6J5DX,%\1UJ`E*U#;>JE>P?V>NK[5";L.-0'M/ M,9,P%EN$KQ#"!1[36:.J,O7"@01$HG,Z`FX#L80ZZ\+S8OS!3 M`)0$BL*#Q*72.`CML=`H[AL(;Z]&OQ"VM7C";SV?N%7EX;(17U#DVZ+^T:&_ MB"+^-9"["'KZZAK)Z:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*U]O M)!Y2LKIYY@/&CXVXB.R#S7R"LG&7?(:Z:4G2>-<&Y03=2LQ+]Z#J/=VJ!A5/ MO7HN"G:PC87]]?)D>/KMKKPK,[A/P1PWX^ZK,WBW6J44+NNFYU.IM>Y`^WGX5EZID3! M61WI*ZAE*O+SIR&9IPD5D1U5K*(K?4)4(MC-1,N=;YX/#W6`\*Q MMNMA\C&`TW,]'UK%'-RB,"&6=PE=9N,#<@$V"11,N:+8B]LV,K>](`;D11_2 MUEA'8A-^FJ-1EH!-TNB_#A_96(921W+VXDRVF8N?QZ>2!\K+MRM^!7L`\;5V M?BMY(.-W+22?4*MRLSC_`#-#EX-3=F]U]I;Z<5B8+IC;A:-G8DH>6]2+W" MK<"1?Q(%5#D-XVN&_)I-9]D/#%;B+>H!E6N2,>-DHCLLXV\G7BU3=Y(P'F"?YA\4:Z)G,YC?*B#ZTW*CUY$!,J=X"!SV$(F/1) MUE(5T5-`H=Z[`J8".J"2F?!3='YS8Y%;:[:=YMM]R\>Z[#O&R M[*+NQ56\TV&I3PN">%M:D(H=^J>2ZS'7&D33.P5N4]\K.29G,8OOLW"C*08. MVZI$GD;*13]%1N[:.$TG+5PD=-4A#E$`KB`.%;0A3H<^$W.@O>9%6;'T'@4G MP(.AKN>H:N.G+A32E-*4TI32E-*4TI32E-*4TI32E-*5%3YA_((V\=O#NTY/ M@%6"^9KV[/C;!T4^(1PW_GB78.'+BTOVAC![\1185!>16*(&(HLF@B;HMK-. MWFS7M[;E;Q+FD1/YCA\$CZ?;:L5WMN=O:^&5)5_BG/A:'B?I]M8D6_RU8^W>#7!QJLWD;G- M3SYBB?V>(`^H^JU;#Q=@_P`VW]_7;_IK55K:5L8>-6TR5A_%V8(1:O91H-0O ML0N10GVEH@(^7]KO*8GN,G+E$7D(FS'QOR59)"U6;$L`L[( MFK;,,7B8^\L;2M1X.-EH]^X=-F8`4Q]V_<=O1JZH1ZT'^Y_BOJ1ZJT;NJ-O' MM`/YJVT](R>QDV^;@NGS5QT:W>CN<0$C@DZ#3CRELPAFC'_(3%E+S'BV:)/4 M:]PC:9A7O;[+I,#B*3R,DFIOXK"6AWR:C5TW/]:+A(Q1]`$:L*"P%)^Z=:W3 MMC.X[<^$C9_#/%['R6NM`/&_,'T@Z$>-1F>4[QU17)2C.\\X7:*4OEQB=F-J MIUQJAUH2?O+>M(+/4ZA)2<>=!S^M$33$T/(;_;T+G2+]!M:YTT].FM?AX?O(7)\R\1S M5%RJZ3#D'A=)@TMZYTR-%[Q5WAU&L-=U&0)HI-9HKEN=E+I$*!"O2E5#M!<" ME\AROF[MG[Z38^S3[:\[!]V'NX^"7C6SA MY-W2#[9*G9`BR.3GCS!] MIWI.6PE]I5,@8SD(0B2QDH=NKGX7Y^^OGMW_`-@2NUFXXO=#9/5'9=EA3EN# M+U[WM?5+W"UM+FI._#CFG*G)6^X3R;8\<.HBO,WIW,.MG:'J#: M+S'8ZV@80!JC9EDVCU^`$*!EUDN\5%@6.-WQ:U.DN'@3?V\ZW9V!W9F]ZS@?L#_#4NLI]6HK[I2FE*:4II2FE* M:4II2FE*:4II2M#?SFY$<*K7^T>[TUO<1,3&P,7&PD,S;1T1#Q[&*BH]HD M5%LPC8UJDR8LFR1-B)MVS5`A"%```I2@`:Y.6XIY9>7JM9ZCZSJ:Z&;;2RVE MI'W4I`'J`M7XS,0VFV*D>Z6>MDS'*H1S'/7,>^;K)CW)+MG;15)9)5,W4/4H M^A@$.@^"_$<:BD,"0D`U8^3B.1E6.96D6>AY'B$Q-V0&4(^0JEE3*7\J*%^I M3>1BW'>3T%Q7C*";J90>HZBL+VN*QN3'W'#3UPWH\L:V2Z/+(]'G)T%AXLJJ MVECS)E`\',UG*_"_*4O79J-DH2<#&5GQ?EF$DXJ4:+,)%L:/>V>F6A5J^:KG M*)#1@'[3=2[]-17OJ>/LM]M663FLRXRO%YG!2E17F5-N?+.LO-V4"#][R3J" M>0M>H5O#IR8A^/U>Y7X.>TCD!<\=T+D//#C(*/A^Y9%?5N-D59-C)P5I3J#* M63KDP!8!JNH@J<"J.%5S$$>NK'B1=AT$_#UGC<\S7/7]/>[(^W86>V\EK(2, M;#RBRPEMDN]+9OU)^&X!!&HN>=JF-<\^:404$HKCUS3GGKA04T6<;Q:R4V4$ MX$$Y>]S.LH6.1(0A MKO\`7:M7OC+EV]8J\P68YKC=@6]W%[>K#F.*1X^622@,6VM!E/,_YPDXZTKR M3B4@*T-2LK$SLR:JBFR*8$*/N'`NL<85TY9XPQ\=C<<->=<-[)W!D,-_4'DI M>S<7+DKD.R_[HM8BJN=3YO5<`).NO`VK8#=R?F0RZJHVC:MQ(XBP+CN(,E-S M5ASS?&B.X!]PW:1*+"G*O0*/TE4*!`'U$=7D&8I-P$M$^T_3UUUE\SW]SA_( MBX;`1"/O.+,MT>Q/PGW?KK!7R&^.]Q6^'6=N0?);E5FODKF>AU%G)TE[:)9I M3L85*7?6:$8+-ZQB^#%2';GD&[U1N!E5E!V4W`@'V$*.9$48*RI\E5CKR]W/ MU5K'NUVH3'[>93`*DDFWARKOG.K-\9R(\F?`7`'&Y\6TY* MX\Y9E;QE6W5HR;Z+I,&LI`C<*O(R;,3(B=G4X1V$JD93VR*NF[4P"NIV!5OH M*WH[*3JVOJ/JM5_[G;C1NCO#MO:VS_S\UBYA?DN)U;;0HI!"B/`)/5KI<@\Z MV+@VV#;H&P;!\@V#8/P#5Q/$^NNL3>YOQO37E>4TI32E-*4TI32E-*4TI32E M-P`0WV`.HB(B```%#<1'?X``:4KS-^->5%,O?U`F/\N2;U,4[QY"IF4;KJJ` M4@,'%VL,/7D2**"4.S]/;M44BA\.T`UVQFX1@=DG(*=5(Q*#]=^%;\[W M/;FKX+FJ'^T/UUZ9(^HZXF3]T>H5U774KFSMKR),-)FHV$L""@+M#S<2,S"/ MNPI@%A,-$7L793E-9<5&(G MR&P;DJEL$>Y-;(F,(B1SABQ8A#F(:0Z<"]PS M->&E87+WC+PWQ;E@2F6=;.L#YIKG:X:LL&W(LJ(-]36*_+CRK8%H6'%V_'?( M-9S-R"R8X7H6'<=U>114F&EVETS1Z$W<6,C^GN*I"UHS@'"HR!6PK*%*D'03 MF)129?0C^Z$%WAI6$[Z[V[#+.UY#,W<\RT>/'%PM*UZ!UY)L4I3S!`\/& MUVO%]Q/;\0N,T53)>?B;3E2]33W)>8;##R;*59N[O94$#GB6M0">#[!-@G<@9?\BO(%U'0,GD9S:X_'+JQN6<0$X\N$Z:8 MR5>F/ZDN@J2$1=@G%,%@^A4HN.T1*!1&S8F-YKJLB="HGZ?77+/]-.U79&7R M7=GQ[20L; MZ9L:Z3I7[9`Y`!HF0HF$X@%ERLQ#[8@PR%.JYCU^ZN-_ZB.].W][XAC8FPW7 M9LI^4"\6FE'K2B_2A)XFZO1;A5*X3\'?*NO@U3`]43A^$.(+I9Y*RY0R).E. MEG6]JR+9M'@T0C(I\M88:,8P31)HV:D5AA,'N'57'W#%U+Q\2:W!,0`,G7XN M)UJ9VQ[<=[3MD;3C]&V\"\YU/OG28Z#R0.(TN/PVOJ:GUX0^/3`W!2J/6&-V MS^R9`LJ12WK+=K(W<72U""@N?L>](HMH.OI.Q]U-@VV3%7^(L=97Z]7B'"3$ M3TCXCS/CZ:ZD[=]JMM=N82TX5"G\HX27I3FKSIXG7E>-;.'"^ MOMX^VFO*4TI32E-*4TI32E-*4TI32E46R+K-:]/.D#`59M"2[A$1*!P!5%@X M42,)1Z"!3E`=OCZ:)T<;/IJ2]^Z>_P!']!KQ^\:91EL1Y\H>;6"HEF<=YCKN M2R*)D,`FNOI3)QPR^UG\,FUY$``>U`KB& M'D50MS)E'@U*O[E5Z_E1M<)>JI6;M6W:;^O7"NPEI@GR9BF3>0UAC&TO&.DQ M()BF3<,G9#`(#L._37S;?:4P\MA7WD+*3ZTD@_97<+3@=:2Z."D@^\7JM.U' M2;5L..W2/8GT58UOP@X)XL@+,^R7C[&MJ?6]R63R M%D_D?*1-\NEND$TS$_5+%>]CJ3Z M:Q9OMWVZQ#3\O+1(3C[P_-D32EY3E^-W'=$W\!8#D*C)R_C[Q@R#E]7N*_#S M(?)O*!%1^PB>*TSE>CX^BY),R?8YL.86%B@\9UUJ3V2@==FJ]6*F&P)ZH@(( MTB,E3E^6@O6HMPX7M"Y>%LS`RLGG>2<>9##=_`S!9M`]1(]%6]P!X.;1E:UN MLD[6-;?><#?AUR";W'!1 M'$@G2L\'7A=\:]-B7,U,8L8\VX` M>SF+A&1DHJTP&=;N3)`2.?[8%JC5R4GPD> MV!YA'Q1\"L>W/"V+%G&Z2\JK;/HOR%;-[0]@,9L:0=T; M@\N9NYTW!2`&HZCJ?)'"X.@-K"VE3;?#5?>^M=(^N_MII2FE*:4II2FE*:4I MI2FE*:4II2FE*_E?,TI!D\8+%*=)ZT.)DROK5+)&2:F[1!%Q6<@76N+M@!0I$%(2SRL8HB4JP`L4J1V MPEV.`&``#?KOKZ780_.X=D#CY*/]T5P3F!;*NV_YBO\`>->C)_3OCR\DDXR7Q><)X2N#8ZH&?*5F.2,]Q?.JHB('*U?TY5-F4XAL9Q&KAZ@.N) M^\NV_P"6]Y.O)_\`CY0\Y'K5HH#U'[:ZO[:Y[^+;9:9_XD8]!]5M#]H\-*GA MUJJMC5^#A!-RBHW5#N163.DJ4#'()DU"B4P`HD8BA!V'U`0$/VZ4JTKSC]@^ M1GAM4IB7'DM91.54+!+U6&EI,JI._L5([DVKM4AT_<-L("`AN/SUZ/II5B=V MMMMZ4)CT)A4OCE&.,F3],0[';7%^.H^CTU5 M5,`V#[ILZ$"B("(Z@,9A6BA[S]/LK%9W;'"YV2F9NIZ9EBDWZ'72A@?^`WTL MGVUF51,?4G&%7C:;CRIU^DU*';D;Q5;JT0RA(=BB0H%`$&+!)%$IQ`.INIS> MIA$>NHKV/2FW2-*SG'8O&8B&(6*C(C0@+>6T`/L]%=SU#5S%@`!PM32O::4I MI2FE*:4II2FE*:4II2HNO*ORMS/Q)PMB^X8*/3DK?>\X5'&"RMY@W-@ATH^S MQDX)%2LVDC&K)JIR3)`3J`1_E_Q%RRXPES7QGA:_SD@D6] M%8"[W:WMLO-_R]W'@XY]Q^`]*:<@E1/Y*2H!0.OX3KIR.H-5KC#R"\EV7L9U M/EO-9(XAV[!,K%2MZO&%JA7[&ODFH4J,CY6:>0,1.QCM=(^0TV465!%F^5.4 M%E]U0'L$@^Q?G5?'=/0>&G#W57;.W9W5SV*8WZY,PK^V"A3[L1I!+S;*02;N M1WDWYCP%8Y&T7)'#:(Q'/WE=%Y@R7A+-(7JLT=E8ABGI) MBQPC@[QG84HM%59J5WTX-R:0J(J_GMQPL@DVO\5O\[T^BM(+RU8N/AOR5\5D?X+>>R7!?FO7"7&5*PP;R`)%XCRZH[7]J/@5 M'\CO0\@K[E$A`J5C>"DY4'\L:_="/Y2ZLG>3:2=S[55D(@OD8GYH_P!(?O!_ MJU=>V.Z5;?SH:E?X&5\)]'*MYKR(\LY),";=VN#)LWY%MI1MTE>OMK:W= M7>F:V/(P^1AICG;\O)-QY9(N0TO5%CRYW/HK'3R+^3#*/%7DYA[%F+X6NSV/ MH:#JF1>3DE(PBTH]KV/KCD:'I,6I'/T9-FG`KJMUU3$6,DX$RSA#Z>T>J7-" M7TQ4@'J&OHK#NZG>++[+WGCMOX5B.YC@EMZ*)1SX[90 MY%R.EBI(^V;O`!\E2OE)"`;6(U/@!64;Z[H3-L[WPFWL<(ZL=+9=D2W'.#,9 M(OU<1:P!(T-[6YU_*Z\I<>UK09;#AWR_4XT?;$DR\@$Z!7PB#ULZ@=MU&A*V M4F0BTL[80<$?'9%$S804]L`$-3/F[CS/()2>=OH:G)[P--Q59EO!YH[30=99 M9`2I/_.2TH^>I`&J5!-B+6JK7GRFXSALG5[&.),.YOY,/[3AN`SS!RV"(BJV M*.>XVGG#QLG,)MYBSPLT`CA+V!4*JJ5(`]P#%`98O8L$FW'Z>ZO,GWI MPL7+(P^"AY'+.NP$S4JBI94CRB=;]1"@1^($7&H.H-=YA?)5@BT5KB?;:C$7 MB>A>6^59+#E/,,3'14G2+K"$>%G&60HJ2DT7,8:)>LE&ZQ&PNE.\.XH&((&U M-^9B_"J^KIM_9[*ND7NSMB9!PT^*)*T9F8N.V+`*2XC127=>"3II?QX55>5_ M/FI<5(]_K\*KME]QL)O%][#MQY<#<$5(4Y$EI+ M3R4_MCC<'C[;\*C]XF^3W(N9_(1F3C7>XRLL\..;7E:E4[:Y$EP%24@\K?H-9!T[RAQF1<@V.D8Y MXB\M+[#5',,SA6QY-J]&KLMCN#LE>L25>FI"4EVMG4<,HF,*L5ZN)TO>39"! MQ)OTT,G7H#)O>U[:>%9;C>]#>3S+N*Q^#S3\)J6['_P"JLH5W,VUC22(+V).03*-O( M#*=%6YAP?B%M%:<=*MICSR8RF4'55L5(X2Q%MZ5*4=+$,:0,B":;?N5-V@40U2M24JNI+*NB_'37Z[Z^JK?AN M[1SC[$C&[?S3FWI+G2B8I("""=%A/5U=*AJ#:UC5X^1GD$P;QESEA#`=_+87 M%NS6]8)-Y2&:L5Z]0F$W8&M2K<[>WCI^U5CXRQ69P9HV,B18XF1.8Q0*`;U! MD(0Z(Y^\KZ:^%7?=O=/;.S=R8W:V6+YR.1<"4)3;I;03TI6]J+)*O6;:\*N: MIR@J"?+EMQ"/7K*-]U_ MN=P;:]\]*5?*\^/T_P`E7M>]("=\_P`BN>?_`!'Y#YD%(_*Z>HIUY^FLH>OX M_CZ_XZ]MRK,['IMSM4)/G2H%FR3QSP;6ZY5;/;?>Y1XX";95.'EYB090+J,L M<=)R2Y89JZ=1S5!)X("[$"D0.8H]P#MJ@FIZFVP+_P"(1[KG[.=<]?U%X*=N M/:F-@PF7WU',1_,#0-P/B%]/6/1XZ5?7%7CGXA<(@OF=*=CS(V3;G%TBSMSN MK=-3N8KPK6CQBZTI4:/`OP.V5>SS8IF8))MS+."JBD93L.?>MC1(L574C0FY MOQXG7V5D.$[3[$V$W*ST:')FY`1G+=9,ET-].K24V_%J+<[ZFH@\=1>,CN3SB2CW%D>)"Z1:QT>9 M5)1P=`&9"*`&]K90E4X?P\*&IZN('C]-*T1BXN)5W$QV9[28O-062\O^)M., ME$?R+"X+1)U^]8"W*PO5(M<-C&\\GL'7KQF<>>5O'3DJ[S1#.\Y1\OC2W8VQ M!$XW?O5EKNO?XV7][(`7T_/`P@H/7^+D-?J\: MIIL+$3M\8W+]IL3FL3N?YX"7ULO-1"Q<]17J0`>(``!!.G"HNOZIG")J#SNQ M[F1DS]J'SUA.%!T]33$$5[;BV2=U>42,<0V%P6MOH@1#??M`!UVQ_3QEOF]L M2,7I_JXZ^VF<8W*.%4YG,C8H9Y'IUR8]O=4PK-UC;BZ$0X1[U]O$[>RYEP@? MX+,)O_]=85L+:^>WUL;=&X]SQR MQG,E!3&8;(XIAM#RR`=;J6E.OHK'?!W%?D]SXXY\P,MWVG3M0S$7!&#>,>$Z M[?R\DD6#W M3/"NQ3_3NHDW#MU@VN#>Y'*HGL2^.GE;%93B<+5K)>1,!Y@IOCK071R#2BO6])= M7RUY9LE@>X0FKFW;?;$ATV<^1!P>-=D=-5FP+I]Z*8@>BC1%=:+W_NR+R!YPVKGE'83RMB3!V#N)5PQQ4'>4*@[ MJ.0,Y620D7MM55C*2H*\\:`A46PE;"X)[BC@Q`*7N/V%J?+O.7,M9"46\`>? M#T<*RO$NYS=&_P!_NK:2E6ZMOH,C(9Y1M+048R65+ M]N\O5[@A@;D]+4.XR_([)7D2H_+[(D!%UB;?7 M2-8VBNQ7%1TJ_XJI*%>\B_N MJOE;/SD7MSB=WR(\I>ZY&Z6\B\@@EY/6XI/3;B`E`&G('E5>XF3=2QYF?.%; MRB]\B^/KC;NQ=+YO\S^\/+X>/V?HJ'8ZH^.W!D(>5:WSDA:&HOG?(J"R2 MDNV MQLO)[77A,X]GG9TXMA,12FCYUFT=3IX#Q-N58K.O'AR0">K?&$\/+H9`4\7% MBCUI5JUD!I*&17>;)#)R.)!NA6YZ]]R9,X10I_<=IN\3A_"^K0PE$=%K?"1; ME?C:L25VIWBU.9VHAISY]>T5MJ4/W8<2\IY,=2N`4;])/#JUX:U.CQJ\A^.U M:MB7"5QPAR4QQG&)B:;CB?Q(/'[(KPE=D(=DQKCZ9;V",A5JJ?'\>=H*_P!^ M#LH)-1ZIB(;#=T/)#82K[XMRX?0UT9LON9C58B!M[(0,M&W&PPVRY'$1\I;+ M:4ME22!T^62FZ2.7(\3&O/\`$CE_SD2YX9]?!5<3MLQ6%QCFCX^S+C"WFRO" MT+C?*MYW&*]#E0G8)"AOK!9&15SN%6;LJ[LIE@[DQ#NM28\E]EV7>RKJL.)L M";'CSY-OH:DP-X3L=O_&[UW/B\F7'] MLAE]3,53I+R7>F]A;[Q!-O3;A4_E?Y`5"Q\?W/(YG7,BM:4VHEDR$:M2E$G8 M_*1X>K,I1Z_CT\=.$2V$]F=IQ"I6<>!/N'1SI%(&ZA=7JYMUZ\+UU0QG8C939#494YU`*)BMD+.A#F-U``]? M7KK>'8'+C'[P5BUVZ)[!0=>+C?Q(_3>M3=Y,89VW$2AQ8?!/M_M'UUY^X>@; M;?AZ?A_9KMFQ&BOO5RN>-7\XQ"AU?TJ>BU MP^WGJE8FR9B??5RT19U&CQ$?]L_>790A#%QC=&V(6Y<1(PT_5,@>[P/K'(U= ML'G9F$RC$Z$?C2H:>/Z_;7J<\#^;&).?G'.F*BY<)JSN.K M_'MT?YCI4\D40,5Q'+J@HV7V!-\R51<)[D4#;Y^;IVOD=GYU["9=)#K1ND^* M>*2/6/;>NS\'F(6<@#(1;=;@`-N2KGIMOTV^6WIMI2N/T;=OMEVWWV^`#\P#;H.E*Y`8`]"[=`#H.W0/0. M@>@;]-*4[_[/WCI2N(B41W[`W^(C^;IZ;&]0$-*7-?=PWW[0W^?^;?;;?N]? M3II2@"0!$P$`##ZF#H([^NX@&X[Z4K[W!Z=O3Y;CM_=I2]._UZ?LZC^_YZ4K MCN`@(&*!@'KM\`_#2E2;_P#"G)__`-1V7_Q=1?\`[Q_P#9/^X_JJ3CQ90'EM\:W(%O>XK@KRQM&%;L>.@LZXN0Q98RDLU< M1<""%EKR2[9-NUOU03746CEA$H.2=[58WM*`9/6_<:;V]WS@RTYELC(M$G1&4Y!2:2$A#R[4%/;<-EB%415*8HATUQPM/2LH MT-B1IPT-M/1X>BNF4GJ2%6(N`;>%5_4-14TI32E-*4TI32E-*4TI32E-*4TI M32E-*4TI32E-*4TI32E-*5R^O_5^_2E/K_U?OTI3Z_\`5^_2E<=*4TI32E-* 94TI32E-*4TI32E-*4TI32E-*4TI32E?_V3\_ ` end GRAPHIC 5 g40511logo.jpg GRAPHIC begin 644 g40511logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`B@$!`P$1``(1`0,1`?_$`,\``0`!!`,!`0$````` M```````)!P@*"P($!@,%`0$!```'`0$```````````````(#!`4&!P@!"1`` M``8!`P,!`@@*!@<"#P```0(#!`4&!P`1""$2"1,Q%$%1(A676!F:83*S-'06 MMW@Y"G&!D4(C,U+20R07&#@W.O"AL<'ABLE,E8S1T_]H`#`,!``(1`Q$`/P#(!\:?C$\?.5/'EP@R5D;B'A"Z MW^^\5<$VVZ7"R5!M+6&TVF?QO7I.=L,Y*/5%GY]D-XQ?J.<=OH_C=$3[(;QB_4,7ZCG';Z/XW1$^R&\8OU'..WT?QNB)]D-XQ?J.<=OH_C=$ M3[(;QB_4,7ZCG M';Z/XW1$^R&\8OU'..WT?QNB)]D-XQ?J.<=OH_C=$3[(;QB_4,7ZCG';Z/XW1$^R&\8OU'..W MT?QNB)]D-XQ?J.<=OH_C=$3[(;QB_4,7ZCG';Z/XW1$^R&\8OU'..WT?QNB)]D-XQ?J.<=OH_ MC=$3[(;QB_4,7 MZCG';Z/XW1$^R&\8OU'..WT?QNB+X.O$3XQDFSA0O!SCJ)DT%CAO0(X`W*F8 MP=2B4P=0^`0'XAT1:N/YPEO_`(]9/_V:P?\`U/1%M,_$G_"[\>?[FG'/]E57 MT12%Z(FB)HB:(FB)HB:(FB)HB\W7;E4[>$B:J66#LJ<0]/&R:\#)LY=LQD4M M_6CW+I@LNW2?-Q#91$3>HF/0P`.I\UMDU(4U<%%$TB&45.1-,A1,=10Q2$(4.HF,NVVV^X_^@=2G.!S`DM:W$D+RCOT M4)45OD9\M_&CQTP[2'NCZ0R7GJSLT%*!QYH*B#J\3JC]46T9(6%4R;A.F5YZ M[,5))PY3.Y=G^0S:N5`$H9_LKIWKN]Y1\B6V^DLJ9;F;RL8T<:$T!<.SES6) M;EWAIVUVB.ZK-J+Z9(8\7$G@78X#O[N'%6S\M*/$6FX_[XD3Y;(MXUO6]M M[0>[2=CQQW=]&:.OY&M>_-0`B$.JQC10$/#"FZB(&!QY58^N4&FQ\17*\R1CX.GTV/@Z_%QK M%$-DF<3%E/$0[-ND7V$**9=:SEFN;F5US>/?+IBM:G:)F35V M#X"-S'_!JGE>(Q4!Q\!7]JL]QN!]O4W-C?-:.;(G2_!@ M3@Q1(/#"V^;\X4N\8A144-\D6_ON2:Q781P)MO85P<#?!OJ2VY:<)`!W$$?B MK"[J5LJ.7Y74[J2SD=P%W#);AW]TS1M#ACB14#FJGH8^XOYLAQF&E)P7E6"> M!TFH^`H5S8.`4#N`Q)1@VD$]S!UW!0!U,,%O)BX,=X@8?!7<:-LW<,7J,M=- MO8'BN8,AD!![2&GCW*B=G\<7$&P@NI#XSDL3U#<-S"M&U/-TC%YYIG>02G(S5@S;BTFTUS18QC/:U$@:.+G-;2AIVQ@55P7&;SB\*\_.&-=MUBE^/MZ>JI MLB0N5RLV]9ZQ^08PRU:*8%OD[2!HU3?IV;]-7&'4+244)#7=AP*R? M9_U)=.=URBVNIWZ7JAP]*Y&5N;A3-PQ/#@IB(]^TDFS9\P=H/V+UJB[9/6:Z M+ID[;+$*=)RU=-SJ(N$%B&`Q3D$2F*("`B&JO+3S!U6K?T4S)P)(B'Q.;4/: M06.'[I"[^BG)HB:(FB)HB:(FB)HB:(FB)HB:(NJ^_,GGZ*X_)'T1:<'1%M/? M$G_"[\>?[FG'/]E57T12%Z(FB)HB:(FB+YF-V[B(]`V^#?V]/BW]NI,TABH_ M]'->\JJ#7S3>7:O>-_$Z%0QVM"V;E;E>&>JXV@)`$W<3CVN$]9D]RU=60&_Q MHV.=`9*)8'[?G1^F8##[N@OK;/2SIO=[\U,SW0]'0+\[;;%A_HSZFK3T:Q@QH3AF_"N!\.-CO@\\3]F7DT/)MSX),Y+Y-9< M=A?\5PN2S*2LQ1V,TD"[7*MJ;O@,`Y%LC%0IHEL)2HU^*,D"2:;@^S?).JN_ M;0L;LC9H;%MRW.20LPSN&!;7B6CGQJ<*T!K9MA[0G&;<^Y`9=5F;5F8DEC>( MH.`[L*\^Q90TW*3,23NB*N_L@BF"AD64G"L5`/N8!(4TT_9)"80*']\`Z_TZ MT-&T"H;@UIH/<#[<2<2ME7%Q<1,:6Q.E`;^DQ@\\/.]OVYJA=HY+L:!ZB^0L M.Y[K4.B4QGMCC<<*Y)@&*!-A.Y=JXFD[Q*MFI0'J<[,H``"([!J&67TSB#[J MK'KG=T6FM,NIV.I16HXO;#ZS1XBV=*\>.2G>OW\0\E^/>>BN1P[F"A7]XR.= M.0A(2P,_UHB%D@#U4IFI/3-;-#K);[&(Z:)&*.X"`"`[&31S>6H#Q[_BJC1= MX;7U]SH=&U*WGGYQB3^,T]AA=21O>'-![E6*8@("U1;J%LL+$V2&>D%-Y$ST M:SEHMVF8!`R;AA((N6BY!`=A`Q!#KJ86$8/H:^"OD]C:WML;>_B9-`_\S)6A M[3XM>"/@HP,R>([CU9)%Q>.-TM=.%^82**/F%ZX\STA5()Y(B;U4_P!9\=LW MS.LRK#UA$3D:D8JG`1W./0-4KK5N+H:L>>8_`X+4.N]#]K73SJ&U'SZ%K8-1 M+:.+(W._3ZD)/ID`\,K6\7<5'_.<^O(9XQ[C$4KGK2&7)7!DO)!&UCD/CYDW MAY]VW[CBDBJY3;,8-W8DD/\`$4B99!@\6*010>N`#N&VNN+JRE`NAZD!_4.( M\>'N-%J2\ZI=5.C>IBPZF0#5]IN=E9?Q,#)!S\Y:!'P(\KFAW'S"2"X'J0&K"/NG-H[QT#?&ELU?:MTRZM'?F/Y7,/]AS.(([2*'&A M(5?BD(80-L.X`/43"/00V^/KN&J@DC#DLDIZAS.P(-"*X>T#`^U1(<[?#WQP MY@1TS;*M#QF$\\.$W#EMD2JQ::,/9WWI`5%ID>JLSM6$^S7,4`.\2!"23`1, M"J@!Z8VB\TBVO/,/)-VC]HX>WBM#=4OI^V9U"M9+FVB9I^YR>?AQS:OA');21L./XMR#I_B*S2;R1Q_:*RZ6%, MEMPY:W"2BE>*[!/=(S4H-B.`,B\:>H`]ML^>N=*D$-P"ZWI0>/:#]O#!L=4 M4TE<@MYXIX_6:ZK*5IS7=&F]3]+W'M%F]=LM-UIL+:W4(QN812KJ,%:N9QIP M]U&KHFB)HB:(FB)HB:(FB)HB:(NJ^_,GGZ*X_)'T1:<'1%M/?$G_ M``N_'G^YIQS_`&55?1%(7HB:(FB)HB:(J"\G.0=`XJX%ROR$R@\%I2<44V4M M:+R@9$Y=\I&IK M'C3&5AB\JY#@W7K.JRM*B\7;X.P1&$5`Z1JK7F\9[PX;_BK,HM0%=Q>&,;K+ M?^IVW2W8C=HZ/2/4KH>F7`U-!_U'FO-U<*?J(/!<^;,M+G?>\)=?U#SZ=`*@ M$4!P\H`H,?C0=JV$B2:92@!`[2@&Q2%W*4I0```I2!L4I2@'0`Z`&N.C. M)K7'$XE=(LRN`>W#"GV"^HE`?:'MU,&&`45%P](G00#80W$!`1`0W]NP_!OK MTDGBA!(I5U/$JP_EGX\^/W*E#]8Y*'.24`.]F_,J42;^D9(^RA:2XL[>Y<))0[U6C`@D$?&AQ[5K7>G2W;> M[K?U&-^0W`T?P;R"L4S'XD$N86EXJ:D.)\0HO,%>0OD9P?Y%->%/DJEFUE@9 MA9HCB#E0BU%NA,PL@[%C!2EQ<'313E8%XY`&SI\?(?"LD8KD*&*\FM M+@6U\![.2\!E/%>/\`,]#LF,\GU6*NE&M\:O%6&O32`.&3 MUJH7=-0AMRK,G[-8"JMG*)B.&RQ2J)F*\YT)?&OZ7NC0[7<.CNSV-W$)`:\">+3V$'`CM"J\(`/MW_M M$/@V^#4Q7NE58'Y$N#%&YR8%FJ-(M8Z-R?7T7LWAZ]+HE]ZK-N*B)THYTY*' MO"E6LQDBM9)MN)!3,58I?613,6EO+9EY#Z4@K0U'<0%JWJWTQTWJ?M:72YXV M?SB)I?;3'!T<@!H,PQR'FT^6M#2H"PNN#_+;)_CCY1OY.;BIH*^SF'^/.0>) M15!-669P<@ZCWR2#5RHFS"U5.62.K'N#"4IR@HB)O17/OBEO-)IUZ7./\.A: MX=Q_;]R^;G3+J%KO1??+V:@)#8,E?!=P\I&X@FAP#@:$.I4>!*R4O`1.Y`L^ M`L_6>4AG-?Q+9N1UNLN&84_>,=#,;`49.YPM;%0A2FK\3-N$D"F2`$!>$<`7 MY0'U?=!:\0RDU]`O):NV/I?N]1O]L:IJ%S&^'1KC5Y)+1A/J2&]C35H)4 MJETY'PF(LKT['68B(4^`RU*&@L09*44[:?/W`J`N#8TM#I<`"I7AZB0ZL3ZQ MQ93229TT5".DQ0-=I7MB(+B`W]O(?AVK>-_NJVT35X=(US+#'=ORV\]?X;W_ M`/Q/)P8[DVOYNVN"N6*<1';<-A'IN&P[;=>FP=0'7H<'C,W@LL.%,<^)/^%WX\_W-..? M[*JOHBD+T1-$31$T1-$6&K_-<\O7$;#X*X15>441+9>[.^7$FJQ"`K#P[YQ7 ML6PC[M^69!Q/HR>^@(H M>1JM%]9];]*V@T*%V,E7R#]T/$0'KU`1`0'IHR1CQ@/-XA7FTU33]1H;.>WF817R/#G>X'#VBJC'\R7$ MR&Y,\-KQ/,(A)SDO!$9*Y3H;\4.]Z:/AVA7-[K`'$!44:6.K-5A!+J'O;9N? M;Y.J/5+_*2I=3*@;8>H;?&(!OO^`?;[-7-S3R%5O@G$85]JAH\Z6`8K+W M!6VWLD>56V\?I:,R;`/2DW=)PAW;6OWA@10`$X-G5>DAYNF-QJ+6M&H:81,QU>##1LC>\$4-#_95CG\NG MR*30Q=G_``9=+&PBH/'<[!Y0J[B=D6L>SBX6[D?QEH:%@DG8[F M`H*O3C[3"(T&B7H?&^U<3F.'TDS*<5(6COW.19<5"_[#W6D-9Q-% M41Z`"JB8;^T0ZZNDVJ6$/E=*/4KP&*Z&UOK1TPT`O9?ZQ:NN8^,<1]5WLR9L M?:K#)SS(Y2SRHZK/CVX3YCSG*K'%LTR-D&%6I^-(Y0YA2(\<^@N9-9`@CW"# MR4B]@#K\6I<>IFX>8K>)_#\Q%`M:S=?-2?!?)[%&=FEZY;?J$3+G(:%5RI+,\=BW+!Q1F;\:NI%.DXYF MVBRS#5.*1,N9NHZ*IZ@'.NJH)SC9-1AF#RV[IG>WEA]OL5Q-UPVSO30-Q1:W MOQMJW7-4A,KVPAN4',6XAN`=0`FE<36I.*RQ/!]EE3*GCYQA'N/1))8FF+=B M-Z"*::/>WKDF64KRQRHIID%92M3K0%#B`F4.43&$3"(C?=%?_P#7L8>#,/8N M\_ILUPZ[TAL6G*+BU+[?RC*/(:@D#BZA%7<3Q/%50\NE,JEP\>')I.TG:MOU M5IC>]5R37$$UXJY569C9*L.8YP02K-I%W))E9I'(8#C[R)0'KJ?J<;)+)[G5 MH!7VMQ!60]<;&UN>E>K/NVEK;:V$T3P:$31.#F%IX@EPH:<0:'BN'B/Y"7/D MOP8Q'?LA/%Y2Z02MCQQ8IQT(G=V1U0I=Q!L9YXJ/REG\A#IMQ='$1%1T50XC MN8=0:7,Z:P8]^+R./@?O4KH+NV_WETST_4]3 M+C4E28:KEN1-$31$T1-$31$T1-$75??F3S]%2OEC<4'H/8>$R.ZP[3E`$5$$:_BANE0&@M2@/:"3N9C'CO8 MO05')C>TPCKZ`]*]-.W]@6D+01,^)\[@_'^(YI=PPP%:`?%<=[^U!VL;TGD< M:QQRMC:!A1K3EISQ(%2>96SXP14&6/L(8=H<P!VWZ^T0`=MPZ"/3^G432`H^$G%/(TDM.63!])0L MBYC'/;*DS<8]MXJFW$5_UKH+FLV`5^XV_>+@1WU*?%&^E12G9A]RQ74=@[/U M.4W%S80-N36KXLT+B3S+HG,)/83566.-!XV\9,[99BN27+NDP-*QA;'S6 MLFY"62X5>1DG46O%05;5B\G-KN=9I.S3]NT%$JQ3"578@E'J%'W\%KC?>T]+VCLK5M7AU368;9EH\^D+NK'']+!ZC'N\Y_AD5Q:XC MO49?@^XJY^L?&*\90HG)W(/'.$O.3G3&,A*I1<:V^+M*5+A8Z%6A>68<2T]BF-=\1.7\B4Q%/)QFQLF(``?- MV#N/+!8N_MV6_4M0W_BZ:N#[.Z/&=W^$`>_S+HAVP=\/%/ZMU%H__FM@?N4; MWD]XWY"P5PRR]DG)7D#Y8Y45>,X>F0V/9N9H%4H=QF[A,-(8D1/0%3J$6:3B MRQJCEPLW!4H&30,(B&VX4]S;.AMI#<32.!;0"H`K7GQ6G>MNTM7VSTWU'4]9 MW/JU\PAC&Q/,3(W.>X"C@QE7"E3EKRJHP_"CP!Q)S/L^<9[D!5)BT8VQY$4^ M+AXYE9+!66+VY6!Y)2"J+Y>`?1SF11C8.*(<6ZB@D(9T0PEW$-4&F645PT^H M/X;3RPJ>_M"T;],/2S0M^W&I:CN&)\NCVS61M#7N8'S$YB79:9@&@X=ZRH\8 M^-W@IAY9L[H?%S$C&1:=AF\K,UM*WRR2A"]I5B25P4G7B:OP[E.&P^S5]AL+ M.`UCC8#X`_>NZ-*Z0],]%E$^GZ+8MG:,'.9ZCNWC(78W8,8UHBR8-F\>S M;E!)LT9H)-6J!``>U-%L@1-%(A0]@%*&VJC(P$5P:TU`X!;#CCC@A]*W:UD3 M1@&@`#L%!R[@L,#^8CR'$6?EWC2@1BQ'#W&.%F:4V*9P,+64N]DD)IJR7V_$ M53AV[542#\H"KE$>@AO8-;D8^[:VN(8:KYO_`%A:G:7&^;#2X>.PMKJZDFK,[+F::-:8VG%Q-#1HJ7*.'FMS?S+YN"#1#-PW,`AN`@9)0!Z:^:&H!S;^=C_P`XF>#XYBNY[-P?:1/; MP,;3[P%ZG5(JA4\O^/8Z],T0-,66K3L?W*0EMITM\SV*#6-OW';**HO(N2:+ M=`592#9XQ7``]1$VP"$;2J#4-.9J$!C]62"7E)&:/'O!%.XC%6E3MYYP8+47 M/*8KJG+Z@-Q%1.=Q;*QF*,YL6`&Z?.V.+:\/CRZ2"9.GJ1$S$F7$NY6)-P*, MB9\S3F8S/'W&A]RP>^U+J!MUQ<;.'7--;B#;O$-V&\*&*0F.3MS->PFI`9A5 M>=A_*?Q%3ERUC*UENW&JY@<$5JAR2QK<<4OB+AT.1&Q^7'.M8X+\3;+&I\>J/8H^RY]S@H]0;5F9>1ZYBM$X#WA=) M2R1$`8JHQB*)3C+S`%5`"M&GO!J">=]_+Z%E3T&_G<33F*4[>?M6@NHNZ+CK MON2+IILB=C-KVTWJ7EX7!L;S-;B1@5J-K5?:;E45.U8I;*R#UR4"E=2)$R]XRY.*/FR#-W?;`@U-(M6[QRJF"L76V+9O&-3=W:=)J M"@``G'5VMH8K2W;$YP![^9YKKWI!L:UZ8['M]`F="W4#_%N'%P'\1XQ!('Z1 M08]AQ*KY>N7O%O&:"B][Y$X4K`(_YC>4R54DGY=@'?MC$Y5604V$-ODI&Z]/ M;J)UQ`W\TC!]O%99J74#8VCM+M3U?3H/W&[- M^E6\CS>89]LW<':0^-:?.OF+M\FFJ#=HXLTZU@H%JW<+%`IUB++=A![@`P[` M,B2]LPTDR!X`K0<:_'!:MW#]3?2;0[:5]I?.OKT-.2.*.2CCR\[FAE*TK1Q/ M,`A8@)JOR@\C7(O)=SI..[%E?*60)MW=K3'UM%$8VJ0T@\"-BFCR6DG+&-@: M_#LB-X]J=PLD!TT`VW-N&L;+9-3N#-$#ZH/LHOGC)IV]^M6]+_5M&M)KJ_EG M,C@W\K&D^4%SC0-;@,3V!3L8G\'/*C/CFF3'/'D(M!4^EQ<9!U?$F/I4EDD: M[6HIJ@R95N!7*V;XXQ\R08HD3$8QC(G.)-SF$PB8;PS2I9Y&S7SC1H_*W_B/ MMQ75&@?31O;<[+=_5'57MLH&!L5I&X.+&@"F5U#&S]ZC7$]H.)R(N-'$W`'$ MJDDH>!L>15+BEQ14FY,A3/[3:GK=,4R25LLST5I><=]1$@*J>DB!A!(A"_)U M>(X(K=N6,`8+KG:.Q=L[!T]FE[:M6P1Y?,\4<]Y`XR/(JX^X=RN2`H`(#N/3 M^@/C^(`^/45!6JRT85IP*Y:(FB)HB:(FB)HB:(FB+JOOS)Y^BN/R1]$6G!T1 M;3WQ)_PN_'G^YIQS_955]$4A>B)HB:(FB*T;GS,+5W@]S%G6QCE<1W&'.;A$ MQ!V,10N,[*4AR#T$#%,;XB8]"O9&D MYC;/_P#:0M185$IV94/:4[8$=AZ@!3MP3#?;V[`/]>OI=-(7SMB(`8)J#O&7 M*:KAMLSF3N?SS5]H=7[UMB_%9FI'D%XZN'N4"KD7>R6#Z;7)T04!0Y+-06/Z MA61-80'<%PFZTN)@'KUW^'7SBWUIQTK>&HV9#LHNY'"O$M>XN'P*[?VG>MU# M;MI<-()]%K33M:,I'P4@.L360KH/WI6**BYD7*Y4R@84F;=9VY4ZB':D@@4Z MBAMP^`.FH@,*J7)-'$VIJ7\@!4E4$MN3\M]BS/&/'VP6>0$QTD96_P!NJ>-J M@B<`#TW#ER"]JN2K',*SK(G!S-G+[T6/-C/;;_A0F]0D/^6_C9%OJ31I)1HX M*NV)?,H6<9#(MU*GV%W3;)PB'>43%3*.PEIGP_-@>N?*/T@4!\:U^&"P/6NF MNL=0`VVZAW[':$UP<+*T;DC)&($DTF:5Y!PS1F,4KAS7JK/XC_'3:&+!@XXP M4F$4CF*#%A*T^1L]-FTDFR144EE9>M3T:]?/3E*`J+N#+++&^4H8PB(Z/TZT M>!_#;0>(^Y5,_0_I;/"VW_E,4+`T#-$^2)Q#109C&]I<:$. M%*K(W:9Y,3CC[#V=RP[<71/IKMW3WZI-JVIZ-IT0JYS;U[6^P/#G$CN MJ<5`C;&66>1.7B8B\9.7O('GFLQZZ\9:\F9.RQ/1U%,#@P-R*MW3=K7&]:K: M!.\QW4PX([=E'M29AT$]KS3RRB*T?,8Z8DG`^''('->\2'B13 M\%N3;/T@Z=;6D=YK>L7[-PDESWVIC:UKCC^9['.+AP))IS"KR7^7RXSR!BGN MW(;E9="]PF.26OM:[1$0'N'U%J@]6(`_^N.O&Z&RN,DKNXFH]@%%E;_I4VK/ M,U^H:OK=PX\G2QG.[M-(B:TPY8+R>7O&+X<.#M&5RAG]E9I*/;%4&)B[CD^Q MR-EN4DBF*B436:C5'-:<6"1=&*`"4B0()`/!K$U,@ M)D]5T>A$#KJ4?+1,9;?VL:T[_P#E5UA:#&T MT)=*ZI?*0:T&!IPPQS%>%'"3#W![$K3&N+&CAY)R!T)6_7^620"T7^R%0](\ MG+JHD`K>/:%,9-@P3'T&2`]I>XYE%%,@MK:.UA].(<>)YE?0?ISTVT#IGM]F MAZ*RLCB'32NIZDK^UQ;3`8@#@!WJ\@"@`[[CO_5\/]6JBJS_`"MK4"A7]V#? M?;KI4\%[4\.2_NO$31$T1-$31$T1-$31$T1=5]^9//T5Q^2/HBTX.B+:>^)/ M^%WX\_W-..?[*JOHBD+T1-$31$T16A>0"/7E^"_,F-;$]19WQ?SLDD3_`$C_ M`/#&RG`O]>VK_M)[8MV:9(>'S\%?\[?P5EW$POT.[8.=L_[BM1FB8`10[=]A M305`=]A_RRPZ;:^D[P))?4&`:]Q'?4KA>0$O->(+A\2L[W^5+Y.HW#COG M#BA+OB?/F%K\EDJGLEE!%57'^44SDEDF93")A;PMYAW*BO:':0THGO\`C!KC MOZAM"-CN.WU^.ORUW#D?@*-?'PH>)+@:FO"AHNG>C6L-NM#DT=U/F+=Y<.TM M=V\L.[C7%998#O\`VZYZ87.;5XH?V)16[/]H6$]O4`#4N2.24#S M92.P5K[3P6&7VD;^U-SVG4[>PB<*#Y:`3.I3F;@^4]F4=II6BH`V\2_&6S69 MI=^1<[F7EU=&BGO#:4Y#Y)E++`LE_4!0WS71*\G5Z7',^X-@;@R.B!?D["&I M)L(I'B6X)D>WAF/#P`6.P]#=H7%XW5-SRWNL:BTDDW4[W1DGC2%I#`#AA0C# MQ5^D:QQ/A2K-8&&1Q]BJE1*`D:1+`M=I%TNYC=!'X1U M4N+(6@/`R\JT'#L6R+:';NAVHL;/Y6SLFC\C=G'RM&<, MJO*W/-<^F8Q$:Y@+'-TS`_77#8`0-)TZ'>U=@83#L)G<@W3)[3&`.NI!NH6N M`&8N)I1HJ?P^*Q^_ZB;>?*!R#%> M#XS<4Z_Q;JKP3MB9@Y:66&LK"^>5W&S8X*>H$8TA&KH\PZA$#[=C M0KEFP,`;"T[=P&&/3#ZGKWKS*_D#^4=X^['DK)HOT[Z5?:DWWBO2`7KOON.O:X45;7"BY:\7B:(FB)HB:(FB)HB:(FB)HB:(NJ^_,GGZ M*X_)'T1:<'1%M/?$G_"[\>?[FG'/]E57T12"BJ(&$.T1`!V$0W';XNFW7?\` M!J,,J*U4()<0&4.)KB,%_?4'Y/XH`/MW-L(?T``#KS*,>U1-J14@_"B>H81V M`N^P]>NP@']`]=>Y13$J7G=FRTKCQ!'Q3U.NVWP=-QV$1^+;;?4+FN`JW$J. MCZG"K0.(//L5-\PU0+]B/*M',4%"W7'%XJAD]A,!@L57E(4Q!`.H]WO>VWX= M5&DRNMM3MKTBOIW3'T[FD8>VBI=189].FMA@]\#Q_F:?Q6G)59.(U56-=D.F MZCE%(]RFH42'3<,5#-%R"0>I1*JB8-M?3BT>9;6.9U`7L:[WBJX0NV>E=RQF MA+9'##Q4G?AYYDAP?Y\88RM,R!F&-;7)#B',!A5,1J3'V0W+.-4F7I>\A#(T MZQHL)@1'\5-DH&_RAUKOJIM<[IVG\+LEOY06T+"*@C&H/-?03[>W8`Z?#^'7H`.'-> M\2`W$K^>H&XA\0=?_#V:$.Y<%Y45H,2>%%Q,(B("&VVP_$8?ZOP:];6AJHFT M/E-0_L7'?<1W`!VVV'J/_DW'45,%`Z4L=0AP;VT74DHEA,M#,I-L5TU.8#&0 M.90I#"4=P[O3.F8P?@$=M0$J"2-D[:2#!>,;XAQ8V<`\3QW23/`4!4'J]8AW M3TJH"(^H5X[:+N2GW'V@;?4+FM?3,`:=P5$_1]+D<'R6\+W#@7,:ZGAF!IWT MXX+WR#5%JB1NV33;H)E[$T4$R)))E_T2)I@4A`Z^P``-&M:S\H5>&-8`V/RM M'```#W`+Z@0"^S3^)4EQJ/!1$`G,?S=J_H%$!WW^#;;;X=_;[=`'#B:I3'#A M]N:Y:]7JXF'8-^GMVZCMKPYL,HJ:_!>.<&BI*X]_7;8-@'8=QZ[[;]`VZZ]( M<'``>5#F`!-,0ACB&VW:/LZ;C_Y@'40`YX+PDCS4)C[L3[ER*81^+;^G<=]> M$4\5%A3F#WKEKQ$T1-$31$T1-$31$T1=5]^9//T5Q^2/HBTX.B+:>^)/^%WX M\_W-..?[*JOHBB(RWRN\FV3O)KGOA]Q5S51:I'4D%Y^JP]\I]1/"M8**J=.E M)9FK.*T^?FG3Q:0L8G2!41*`&,'>4"E#5@EEOI;]]K;24`%<>6'!<9;EWUUD MUOK)J73_`&+>6L+;6#.QLS&!N0!AQ=D>:^?C0DTX*IN(/*1RJX_\D[7Q%\A% M*H$S;(C'EFO\#D7$H"U3?)0%`E\AQR#^/2%2,D(VQ1-?=H)N$4&*[1XGVK(G M((G+'!?78N?E+V,-(;7,#QH*G"G/[!7K;G6G>NVMWW'3SJC!;2ZE':.EBN+? M$.#8C*!D`:'YFC$@1T/Z:U5&>,]O\O?DGK]HY*XSY7T3CACAM.V%_?@W$NKMI<[RT76[72=#;<.9##D80\Y2\P?)7C M)SQ,X,,[=BEES0SX#IY=\M5F"9-*Y"0\G;9:NTN*A@DT7D*E).(Z(^NHGQV(<#=.XGW4]O,^*O&]M^]6=$=HG3)MS:_P!>ZK4R M70:(V,'J.:P-(!:\EK6YG!K,32E<3>IQ@P'Y8? M.*CX0YO,%CHH1AA)4$'LHMD[_`"_'/LO, MGA3#4&YS8/LY\8"0^+;Z5VN!I*P4U)F*B)A&1C%C'$ M/4+OPAUEVHW:6ZC):L(T>]K(PTP8\DYH^=<:&N'YJ`8+KWIKN0Z]MQL$I!OK M:C"*^8L``#C\1[`>:^W._F=R1XJ^17A_4G5QCH_B1F)Y76-BADZK$`Y6DG4\ MO2[4A*6ERW7DSHPRT_$RJ14%&X$((@;N*`[Z3NKF>"_B#@!;NPKWU\/@M6]3 M^H>Y=B]5]N:='/EVA?N:R491B]\A8XE_'!I8X#E3OJ*N^8KF'ECBGA7&,=Q^ MF/FK..9P2$R0B4[L.T0,.X M3-6FF;$R"W.69[J5XX4KP5Y^H#J!K6PMMV4&U2&;BU&]$<1P<:9:FC2#7S.8 M/\555+Q4W? M+%<$OD_N=ZG^;_(#DMDVI57A9BR^C`XD>2-;:MK.64G MI>57K51@GT,D63M*_P"I\2BY]R%N[?'6D"F]0J1!`*>QU1UQZLDC6MMF.H"3 M]V&(P6N^F_6^^U2XW!NK==Y#;[#L+KTH:LQ<\YLK&$>9[B&U#0'&M.\JX1UY MHL:1D:%[E.)/-N/P8H/J(9Q=X2,A3#QW4WSVHFI-D>-X3T_E`N;Y1B]0)OTU M4#4(W#/E<(NVAQ[P*+)1]0NB,MSJ,VB;D&AYCENODQZ):*'/7U*AE#4.H:^. M"N.R;Y/>*6-^,U5Y<(V::R#ABW6V/I$?*X\B4Y>:9620:23P8R;@I5[!NX1Y M'$B5BNT'/IKHG`OR#%.4PPW&IVL%L;D$O`(%!WK+]=ZQ[*T3:-OOADLMYMZX MG;$'V[0\LD+7.RO:YS2UPRT(.-2J:T3S"<6K9D:@XRM-6S]A.8RBNR9T"8SC MB*6Q_5;,]E#()Q39C.N'KU'ME%G:*:"YB@V,HLF!E"]Y=T.I6\LK(G9FN>*B MHP]ZL>E=?ME7VK6VD7\&IZ=+>/:V!]U;^G'(7@%N5V=W&HQ(IB,5-LFU,CA7P`69NZB:'%OV/IU.)6Z_);^L,`8\N5SZ!U:DT:?T@=ZZ', MOG-A[@S3J=>,QQEYDXB\6Q6FPB%#@V=@DPETHE[,C[VT>2T.1-`S9B[@M6YIR0TORB@KC0G[@I?43J3H'3+3X-0W"V=T=S/Z48B:'N M+Z9J8D4%*XJSNN^)SWA=";>)L&=FR]B"7JU52=*CL4KZ5;/95 M1F@G[55CH^DB4!,W'K<.D;7O M-P6SV/;#8R31NXM-&%S#X$T]Z@A\,_DUY#W]V2,?=2V_KVQ#NX?H7' M*6:L,T9(E+!:9!52O1UJ5BL94N+5&47^:)-NY9D^=I)6T-<:C ME05-<%[#$?E#J.._'7QOY;1? M0K"/:N&]4.82(CL510A2E'NWU%%J#1IK+N8&KN7'B5<]$ZX:;8=*-(WSN_UI M+F\D="X0L#G.E:7BC6DM%"&U.(XD8&+PYRLK@Q-)OU]?S5X MP=*5:N(0V.JK)6^;14FGLH=JG).HV*539I'[?7:O6B]<-$UN22*'2MPQQ()1`0WZ:HV:O M;R0^LQKR,U/RG\%C,/U.[(N+=MY%8ZRZQ.;-*VW:8VY7Y35WJX@<:BO92JO! ME_)?Q4:\4I;F56[9*7_#4#)PT'-C38D75QAIZ9EXZ%2@Y>JR[B'>Q4HT=2J) MUDG!DQ]`X*IBH0Q3#7/N[9EN;@O&0?A59]=]8-EV^QW=0(9S/H+',:[(*RL< M]X8&O9Q::G@2OS\G>3WBSB+C?BODO=)NQL:WFV!9SV+*(A"I.\H6Y)ZBFN#9 MG5D'YT4#,R+I^]+K.2-$#*$*97O.0II4U_;0PB9Q)#N``J3W`=M<%*UKK+LO M0=IV6[;V63Y?48PZVA:VL\M>36>-!4X8JW_&_F)J=KO./JC?^(/,'#<3EBQQ M=4QY>+EBIXYKZAP!,ISEI8]7;)(V/T M+@9B!4LP%>W'#O6.Z-UZTW4M2M["^T/<%C;W4C&1SRVI](N>X-;4AU:$GB`: M#$X*^/ESS%P]PIQ:CEK,[B;"OO+)&5.+BZLP0F;',34FDY=%1C8U=Y')+),V M#)9PX4,L0J2*8B.XB4!N5S*VVB]5V/Q>@IO*'%]_XUMN5E5<2TGBIUC28RFF8C`I;"6!K\8_DIF-4B17] M-*Q1YHMPV4:F6``!;7X5598;ST74MI-WI9/=)HCK5\Y( M%7AC`\O<,5W.V+&ED:4JSOI^/CD;;&H0\X5>N3+V# MD#.6#9])(I)F>L3BD(+&[R"`CMOMJ7:SMNH&S@4#A4!-G;QTK?.WX=R:()?Y M?,YP'J#*X9#0X5/-7`OOS)Y^BN/R1]3EEBTX.B+:>^)/^%WX\_W-..?[*JOH MBQ]+CCODYDGS<\M8;B5EJN8;RTRA'LN2WV=D#Z--6D:=B]I-094C5ZT`F[D5 M7C8Y%!:"!2H&#N*(]<>:9G:U(VV(9)D&)&8'#LP7S^U'2MZ:O]2VN6VQ+V&Q MUQMK4RR#,WT\L%6T(..('`\#PXB4'B5XGLC5?D7,\O.;N=H_D;F20K\S76<* MQB%R51NE.UUS37CF6>2+:-&50:5)ZX8LV#:/9,VQ%SGV.?M'5P@L91+\W=O$ MCBRE`VG[3RPX>"W7L3H9JUEO"7J!U&U$:IN*2)S6,:PAK,S3&<:T+1&/N&R7R<\>_*"T5+']00?Y+L^"[,Z4/&DK<&W/(3#1JJZ5 M<4^]-HV.0$J"$K'MWIVB8)E>'4*034-S:WEL/7L'TA&.0_;@L&W/T>W?TMCO MMZ])M9?#H\59G6,U02T5!*7(GFOPWYZT?QY8YR(JX=2-H@V;J*L+V!E%) M>2*%B]3[;I3OJZ;JUC>-)MYP1ZF7&DCB07"E""UQ/#`\SCH?S+.R\G-JN MS9E[I$9YQ3CC)K15-,"HN9>,CW6.;('_N M6/[K=CA0T6IP:J1'Q=<\K#X[^75%SJW4D'F.WXEI&;ZLQ$YQLV*YQXW^>%$6 MH&`CB@N03\H]V605H*'"O`C#CX@8BBSCO-OCFO\E?'Y6N1V*Y-C M9T\2RM0S72;?!."N&TKC:Y-VT9+R<8Y3#O49'82S"5[@V$@,0$VW:.WSAU^U MO8H)(G1TOH)L6'`@-P/X^SN6=?4]M^/<'3(;DTTUNM-FCN6.;B[TR0QP!'`` MN#N8HTBG9:KBC)J7DR\DO!V=*H,K1N+G%FI9MOR28^NP0R]-,6#V1CW13B=, M'K&[NH=,Q1`#B$>H`_BCJFCD%[J,990Q1LK6M:DBBP';^KQ=9^K.W[B`B31= M#TB*YFKYV_,O`(8>`#JEF-#7TSABK;G6?5?'99_,KQI*]&&&V%4MF#$%#"10 M)+*+Y.%%6((`@`*QU$R.T=!V```2'-U^0(ZIA4;8&9+=S?0<'?+@Y7`M&7TZ'"A\N6F'@L!S,B,:QX_\` MD0KF+U#_`/+BR\@.+VN,`9G$\"V>JM\\,E"P`@!FP(C5D6!2@EN4S"^7.XCEVKNFQT(22[9BW-;NMA0^GZG^K!:W*V*>V8QA)NG,8T9?5+RT.<&@T'Y2:4P%+X;*)S?S#]"+N`"/$ ME^()^PX&-6KB`CUZ@4!$`_`.I[VL;K[)6@EPC-:#ER6QIA3ZMK5^6@_DF.%< M!%+A7M[^S#FN'\P.!O\`A7Q#Z%W+RJKP_+$0$!^8G^PI^P1/UZ:]U@O8V$1M M2O!Y=0"GAP4, M,[E*XTC^7'K[J[NG(3MWIL?BJM*N5%/>EJA8B>I('$O;0=HJ,/&GL6@+[6[W2_I,8_472?,W,#8821YBR2: MK&GG0L:6UXJB5NQS(\%<:>&#FA&M5&256BH;'^;%$B"E[Q6\RJRF03DD>P`` M>V"N<^F03AT432#V@`:\DC%G'9W1=D8W!V'$.I^U8W?:,[IEIVP.H-K'Z(C8 MVWNP&EI+9G9BY[L<"U[Q2G``JO&-(%#R-\[_`"!\B0,-@Q+@S`]]XV80<@(N M(A_-V6F6:K_/D0H<`35!TV4F7Y#EZ]LL@;_0'4RU'\TOY9[T^NVKTXW M_HNS"/-E-./9XKKZ:/JS_3.H-W<_1QH?\FN:_+B42_\`ZLE*$N(!#J5PI2M% M^%X+4BK^-+$R*B1%4%;/EQ,Z2J95$E$SY"GP,0Z1RG3.F?T7`;F)-1W*E^F:-DO2#3F2M883+=9@0'-/\=WYJ]HK\%`AGQ*MQ27FRK> M$_=DN/C:\`[E6GAF MWB;1Y"?&E!YI29NJA!<#<H]5=JP[E:'6,6W6NLP]O\/U0 M'%I8#Y<^;AQ)<`LPHY`/N90I3@D(JE!4.X"J$ZE4)T-V'+UV$``0WZ:RIK2* M#,QF MG=[K&+,=3>45;#F"T02@J-9>"@DC@G&1"QF3,ZRP@4BS-TF&XF';'I[ASM0] M-PI>]=(W!UIM]'U.WNK[:.AQO,\=O"9ZW$K2UV=M6CRFC< MU210D`\#T/'%G)C%\8/)+PN6_6N.C\6XXSME+"D=D*OR50N1\0V^JV)!=K+5 MB;21>Q3F.?"T>J(B`AW2YC%,)1`=-/DD,,M@:A[0XM/<1@**/H]N(P;2W3TX MD;-!'90W5Q:-F88I#;RAY+2'$D@5:13M/9A)+X).OC5PP8`,!?UCRJ(`.XAM M_P`1K%L&WM'X=7#2LPL(P\$.R\\"MK?30'.Z3V;I"XEL\XI7EFIV?!2]/#]S M%V.VW^ZN.@[_``(G^,`'5P+:%=`^88.%''OK\5IQ-0KU;3WQ)_PN_'G^YIQS M_955]$7QQSX\JCCKG9E?G4SR/9I2TY5KTA7WM`=Q$,C7(=*095!D=TTE4`^= MW*J1:B0Q2J#V[N#A["EVI8[5K+QUV35S@!2G"G>M3Z3TGT[2.IM]U,BNIGWM M["6.@-W;4DA'G5!5`RJ2A`5(43%,&X#5DX4;PHMGWEM\S:2VD+WP^K&YN= MA\[:BE6GD17#L4#TCX-;-)Q9LK5GI6"Z9@'D=G'BRRX\5.9JV/T<;30+1 M[A6R2))6R6:T)E<0TQ.6FQNTBB\VJS# M7NBUI>Z?ING;8U74=%MM*B+(66[O(XN)<7R"H+G%Q))KS7?XA>*FF<<,QN^2 M.3LT9*Y/\@U8YS$Q>0\GKF$E;9O&)HUTK#1RTA,O322L>H=L1=R]6*W:JJ)H M)I]YA&9!8-@E]8N+W]IXJ'8G1/3]J[@DWCK=_=:ONUS"UL\_!C2*4:TEW+"M M<%"W_-H8'4E,3\5^2L>R[E*/>K5ART/4B!N6(R!#I6FM>\'`.XJ+>:I3LA>O M;WNP#^]KJ/Z\K!Y$VXB.WMUUR\ASB1@%S4TY11?WN#IN`[@/P#MT^$/P#J`-`) M=^L@4_;[TJOR$5K(M$MOB9Y.S95Z?DJL7&"X[3LVZ*8$VEHC7X6 M["H+NS&0(J9-RO*UH!V`%@<-"!N+5/7*O73ILQK9-X:/'_IB*7+&C$`@CUC76P-==2&Z@?'&XT)HYA;E%>8KF;QJ01Q("R:?' MWXRL6>/_ROE<8^P8> MQ:K?T,U>2R;I$F[M>.AM;E]'.,6?V"_-4MIA0CAWJKV4O$KQSNO$ZJW@>:O^_NEVW^H6EVMAJKI8;N MRD:Z&XB.6=@;2HS_`+U/-[QWV^Y[\3\5FG/$#R(@^5'(+$.1J[C"L8J96"BR M,&%D%,:\5BNY^A]ON#<[-UV>LZGI^JQ6++5KX2W,6,;ES.<<2YW%Q%*X]N'C,B> M'9#+N(HW%.5>9_);)!X/++7+-?N]V?5^Q6J`?M*DO54X&'7D6:J+"($5Q?;I M@54'90,!MM]27:5))`V)]S.7M>#FJ*\"**DUOH.-Q[?9H.M[@U>Y]&^;=12O M+#(QS6%E*TQ%'$\1C3##'\8?"32+K+09N1/+[EMR1I<#(H2R6.,BY"$*O(/V MX@*9I`&I%'GHG*':?W<[=42B(%4*`B&ATDR2Y[B>66*E,KCA7#'[#FJ,_3MI M^H30_P!3Z[K.J6$3\WH32#TG4((JW'@!3CB">"NOYO>/BH\R\`4CCJA>9+"M M%HEB@)N(84BNP[V/%C6:])5R$K813\R#=K#QS.2$R()&*8ATR>T`U6W=HVZA M;;M.2)O=6I'#F%GG4GIAIG4';$&UVRNL;&VEC>P1MP'I@AK:5%!0GX*H?)WA M9CSE%Q=/Q9M,I)5NKH,J*U@K'`-6*DW7'%`6C#0TA%MY%-Q'E<':1YVQRG*8 MOH.#@'7;4<]K#DYE)HR2([3B&S M5DFUBXB/0:($*3HFGN/RC#J&QM(["$11<*DGOJH.G'3C1>FVV9-LZ6^2:WDE MDD<]X;F)>`,:=E,/:H^FO@LQ>C@:WX$/R#R@G`VS/<+GXLK'U^H,74#/P-=L M=891$,T.U=HIL3QT^45%CG,N*K-(2B4!,&J3^5@V_P`N9#3UB^H&./(8_%:M M'TU:"-OR[?&J7[;>74A>@M#`62AKF^0&H%^,MP[`<)$[@[>FJF" MS$0(DDD>T@BA.&(HLHTOI!J-BZ<7FYM:O+6>VDA,4KF.CR21NCQ'[N;,*4Q: M.^MO54\&J-*J">.ZQS\YAUO'GI.D'-)JUFB:U7%V\D8ZDPF2*BD48]#YV45. M=<01'U#G$3;[CO30Z6((/EV2R>G4FE<,5A^F_39'I&G?R;3MS:Y#HSL^>%CV MM8[._.["N`/`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`+OQY_N:<<_P!E57T7BD+T1-$31$T1-$47'FAX]&Y+>-'E11&+#YPL MMN6RXD=M[Z@DT*'47,E&PCID4`ZF!T(?#MK/NF&L_R+?.GWCC M2!\WI/[,LP]/'N!<'>Q8COK3!JVU;RUH2]L7J-IQK'YJ#Q`(]JU79#`E8Z=@ M)V(=JL):%FXAXC(14M%OD#$79R$<^;IK(JD$#$4(`A[-2IX(;F%UO<-#X7M+ M7-(J""*$$'`@C`@J=;SRVL[+F!Q;,QP((P((Q'!;,/PG^5:"\C>`RU^^/XR+ MY58;BXR+R_74C)-?URC`*FQBE@3$-U:$4D;_: MY"0=Q_4.1[BVLV6M6+/DT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3 M1$T1=5]^9//T5Q^2/HBTX.B+:>^)/^%WX\_W-..?[*JOHBD+T1-$31$T1-$7 M4D&#.58/8N1;(O(^2:.6#]FX("B#MF\1.W=-EDS=#HKH*&*8!Z"`B&HF/=&\ M2,)#VD$'L(Q!4+FM>TL<*M(H1W%:A_FK@%YQ7Y;\BN/3Q(Z26*LLVVNPAE"& M3%U45)`\M29`A3@!A3D*A),5BC\('U])MI:RW<.VK+66FIN+=CG=SZ4>/8\. M'L7#>Z=*=HVOW6G$4;'*X#^[7RGVMH?:K8-P^,/[=9$K!0IN'QA_;HE"K@.+ MG)S+G#S.E#Y"X0L1Z_?J%)>\H%4,J>&LD*Y[4IZG6EBDHG\Z5>S,`%N[0$0, M`"55,Q%DDE"6/<6W]-W/I$VC:JP/M96T_>:X?E>T\G-.(/L-02#>=!UR_P!O M:E'J5@XME8<1R(#..+'2<;,(BC!91QN\>H MN;'C"^(MB*R%=ERI@F=S'N0'WB+?@0J,BQ.50H%."J27S^WGL_4]E:T_2=0& M:/\`-%(!1LL=<'#O'!S>+78<*$]F;:W'8[GTQFHV1%>#V5Q8[F#W0T5))H.5223WE6.^VSM_4K@W5_9P2W+ MJ5_]PI_16T_]OM?\@5>,"<)>)?%J.'_>A_P#L3QK_`-+_`/TX?_:45_V$?_R3_P#' M_P#Y7Z.B*Y#[WYHB?>_-$3[WYHB?>_-$3[WYHB?>_-$3[WYHB?>_-$3[WYHB M?>_-$3[WYHB?>_-$3[WYHB?>_-$3[WYHB?>_-$3[WYHB?>_-$3[WYHB?>_-$ M3[WYHB?>_-$3[WYHB?>_-$3[WYHB?>_-$3[WYHB?>_-$3[WYHB?>_-$7Q:(O__9 ` end
-----END PRIVACY-ENHANCED MESSAGE-----